From owner-immuno@hgmp.mrc.ac.uk Wed Mar 1 08:10:14 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 9F2C417AB4; Wed, 1 Mar 2000 08:10:13 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id IAA08781 for ; Wed, 1 Mar 2000 08:10:11 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id IAA05762 for immuno-list@hgmp.mrc.ac.uk; Wed, 1 Mar 2000 08:10:10 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: Jamie Cunliffe X-Newsgroups: sci.med.immunology,bionet.immunology Subject: Re: "Danger" or "Alarm"? Date: Wed, 01 Mar 2000 07:58:24 GMT Organization: Deja.com - Before you buy. Lines: 33 Message-ID: <89iiiv$5pq$1@nnrp1.deja.com> References: <38AC84C2.C0BFCAC8@home.com> X-Article-Creation-Date: Wed Mar 01 07:58:24 2000 GMT X-Http-User-Agent: Mozilla/4.0 (compatible; MSIE 5.0; Windows 98; DigExt) X-Http-Proxy: 1.1 x26.deja.com:80 (Squid/1.1.22) for client 62.6.114.232 X-MyDeja-Info: XMYDJUIDcunlij To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk In article <38AC84C2.C0BFCAC8@home.com>, D Forsdyke wrote: > The word "danger" is currently popular among immunologists. > However, "alarm" (Forsdyke, 1995) may be preferable, since it > conveys the sense of a distinct call to action, whereas > "danger" is an attribute which leads one to beware, or keep away. > Anyone following the "Danger" or "Alarm" or "The immune system is dead …." Threads might find the following article illuminating. Here, I guess, that I, too, have been guilty of skimming or reading with blinkered eyes. Ibrahim et al in viewpoint paper in April 1995, published in Immunology Today, 16:181-185+ outlined (essentially) the mess/non-mess concept in language and a depth of understanding that was, to my mind, spot on. I would suggest that all contributors to these debates should read and digest this article carefully. Personally, I wouldn't be tempted to change a word in their article - either in respect of its "plain English" or its conceptual content. It’s a pity that I had not appreciated its content when devising the bibliography for my last three articles. Perhaps I was just not conceptually ready for it. Jamie -- Waterside Health Centre, SO45 5WX, UK Home pages http://www.ndirect.co.uk/~greenprac/jamie/jamie%20main.htm Sent via Deja.com http://www.deja.com/ Before you buy. From owner-immuno@hgmp.mrc.ac.uk Wed Mar 1 17:35:54 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 3099817B32; Wed, 1 Mar 2000 17:35:53 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id RAA02652 for ; Wed, 1 Mar 2000 17:35:49 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id RAA12925 for immuno-list@hgmp.mrc.ac.uk; Wed, 1 Mar 2000 17:35:48 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: Volker Blaschke X-Newsgroups: bionet.immunology Subject: TCR changes AFTER VDJ-recombination Date: Wed, 01 Mar 2000 18:36:39 +0100 Organization: GWDG, Goettingen Lines: 15 Message-ID: <38BD5527.FF0431A6@gmx.de> Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Trace: gwdu67.gwdg.de 951932146 27698 134.76.32.135 (1 Mar 2000 17:35:46 GMT) X-Complaints-To: news@gwdg.de X-Mailer: Mozilla 4.7 [en] (Win98; I) X-Accept-Language: en To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk We wonder if there could be changes within the TCR sequence AFTER the recombination has taken place. Background is that we are trying to identify malignant cells from a lymphoma, but we do find T-cell clones with TCR sequences pretty similar to the presumedly "malignant sequence". So, do we have different cells indeed or might it be that these are "subclones" of the malignant cell with ongoing TCR modifications? Would these modifications be random, i.e. by "normal" mutagenesis, or are post-rearrangement processes at work? Any references? Thanks, Volker From owner-immuno@hgmp.mrc.ac.uk Wed Mar 1 18:10:30 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id BBD3D17B32; Wed, 1 Mar 2000 18:10:27 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id SAA06032 for ; Wed, 1 Mar 2000 18:10:22 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id SAA13425 for immuno-list@hgmp.mrc.ac.uk; Wed, 1 Mar 2000 18:10:21 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: Juliana X-Newsgroups: bionet.immunology Subject: Courses Date: Wed, 01 Mar 2000 18:04:48 GMT Organization: Deja.com - Before you buy. Lines: 11 Message-ID: <89jm3r$vin$1@nnrp1.deja.com> X-Article-Creation-Date: Wed Mar 01 18:04:48 2000 GMT X-Http-User-Agent: Mozilla/4.0 (compatible; MSIE 5.0; Windows 98; DigExt) X-Http-Proxy: 1.1 x33.deja.com:80 (Squid/1.1.22) for client 200.188.61.70 X-MyDeja-Info: XMYDJUIDjuliana77 To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk Hi! I'm a biology student looking for summer courses in Europe. I'd be glad if anyone can help me. Juliana -- Education is not received. It is achieved. Sent via Deja.com http://www.deja.com/ Before you buy. From owner-immuno@hgmp.mrc.ac.uk Thu Mar 2 02:32:51 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id DF2BB17ABE; Thu, 2 Mar 2000 02:32:50 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id CAA20883 for ; Thu, 2 Mar 2000 02:32:48 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id CAA28040 for immuno-list@hgmp.mrc.ac.uk; Thu, 2 Mar 2000 02:32:47 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: "Sara Valafar" X-Newsgroups: bionet.immunology Subject: METMBS 2000 DEADLINE EXTENSION (MARCH 6) Date: Wed, 1 Mar 2000 21:37:45 -0500 Organization: Boston University Lines: 251 Message-ID: <89kjsa$2r$1@news3.bu.edu> X-Trace: news3.bu.edu 951964365 91 168.122.7.73 (2 Mar 2000 02:32:45 GMT) X-Complaints-To: news@bu.edu X-Priority: 3 X-MSMail-Priority: Normal X-Newsreader: Microsoft Outlook Express 5.00.2919.6600 X-MimeOLE: Produced By Microsoft MimeOLE V5.00.2919.6600 To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk The 2000 International Conference on Mathematics and Engineering Techniques in Medicine and Biological Sciences (METMBS'2000) (E-mail submissions are encouraged) June 26 - 29, 2000 Monte Carlo Resort, Las Vegas, Nevada, USA Call for Papers/Abstracts Recent advances in computer technology have provided the tools and the environment to study, analyze, and better understand complex systems. This technological development has enabled researchers to collect and analyze massive amounts of data to a scale previously not possible. The impact of this technology is now being felt in the medical field and in the biological sciences. In recent years, research in interdisciplinary areas such as Bioinformatics and computer assisted medical decision-making has dramatically intensified. METMBS'2000 aims to provide a platform for researchers to present and discuss recent breakthroughs in this area. The METMBS'2000 Conference will be held concurrently (i.e., same location and dates) with the International Conference on Parallel and Distributed Processing Techniques and Applications (PDPTA'2000), the International Conference on Imaging Science, Systems, and Technology (CISST) and the International Conference on Artificial Intelligence (IC-AI). You are invited to submit a one-page abstract or a draft paper of about 4 pages, and/or a proposal to organize a technical session (see below for submission information). All accepted submissions will be published in the conference proceedings. THE NAMES OF TECHNICAL SESSION CHAIRS WILL APPEAR AS ASSOCIATE EDITORS ON THE COVER OF THE CONFERENCE PROCEEDINGS. SCOPE Topics of interest include, but are not limited to, the following: o Bioinformatics: This includes informatics techniques in genomics gene sequencing, gene pattern discovery, gene pattern-function studies, and other genomics related studies). o Data mining in medicine and biological sciences. o Pattern recognition in medicine and biological sciences. o Signal processing in medicine and biological sciences (e.g. biomedical signal processing, etc.) o Image processing in medicine and biological sciences (e.g. biomedical image processing, biomedical imaging, etc.) o Medical decision-making. o Medical Physics. o Biomedical Engineering. o Biomedical Electronics. o Biosignal interpretation. o Any application of computers in Medicine and biological sciences (protein structure-function analysis, drug and protein design, molecular modeling and simulation, etc.) o Application of information technology in biomedicine (e.g. medical database management, information retrieval and use of computers in hospitals) o Application of Computational Intelligence (artificial neural networks, fuzzy logic, and evolutionary computing) in medicine and biological sciences o Medical and bio-computing. o Computer-based medical systems (automation in medicine, etc.) o Recent history (1990-1999) of Mathematics and engineering techniques in medicine and biological sciences, and what to expect during the next decade (2000-2009); New horizons. Review articles) o Other aspects and applications relating to technological advancements in medicine and biological sciences. SUBMISSION OF PAPERS Prospective authors are invited to submit three copies of their one-page abstract or draft paper (about 4 pages) to F. Valafar (address is given below) by March 6, 2000. E-mail and Fax submissions are also acceptable. The length of the Camera-Ready papers (if accepted) will be limited to 7 pages. Papers must not have been previously published or currently submitted for publication elsewhere. The abstract and the first page of the draft paper should include: title of the paper, name, affiliation, postal address, E-mail address, telephone number, and Fax number for each author. The first page should also include the name of the author who will be presenting the paper (if accepted) and a maximum of 5 keywords. PROPOSAL FOR ORGANIZING TECHNICAL SESSIONS Each technical session will have at least 6 paper presentations. The session chairs will be responsible for all aspects of their sessions, including soliciting papers, reviewing, selecting, ... The names of session chairs will appear as Associate Editors in the conference proceedings. After the conference, some sessions will be considered for publication in appropriate journals as Special Issues with the session proposer as the Guest Editor of the journal. Proposals to organize technical sessions should include the following information: name and address (+ E-mail) of the proposer, title of session, a 100-word description of the topic of the session, and a short description on how the session will be advertised (in most cases, session proposers solicit papers from colleagues and researchers whose work is known to the session proposer). Mail your proposal to F. Valafar (address is given below); E-mail submissions are preferred. EVALUATION PROCESS Papers will be evaluated for originality, significance, clarity, and soundness. Two researchers in the topical area will referee each paper. The Camera-Ready papers will be reviewed by one person. PUBLICATION The conference proceedings will be published by CSREA Press (ISBN). The proceedings will be available at the conference. Some accepted papers will also be considered for journal publication (soon after the conference). ORGANIZERS/SPONSORS A number of university faculty members and their staff, in cooperation with the Monte Carlo Resort (Conference Division, Las Vegas), will be organizing the conference. The conference will be sponsored by Computer Science Research, Education, & Applications Press (CSREA: USA Federal EIN # 58-2171953) in cooperation with research centers, international associations, international research groups, and developers of high-performance machines and systems. The complete list of sponsors and co-sponsors will be available at a later time. The last conference's sponsors included: CSREA, the National Supercomputing Center for Energy and the Environment - DOE, The International Association for Mathematics and Computers in Simulation, The International Technology Institute (ITI), The Java High Performance Computing research group, Korea Information Processing Society, World Scientific and Engineering Society, Sundance Digital Signal Processing Inc., the Computer Vision Research and Applications Tech., and more. LOCATION OF CONFERENCE The conference will be held in the Monte Carlo Resort Hotel, Las Vegas, Nevada, USA. This is a mega hotel with excellent conference facilities and over 3000 rooms. The hotel is minutes from the Las Vegas airport with free shuttles to and from the airport. This hotel has many vacation and recreational attractions, including: waterfalls, casino, spa, pools & kiddie pools, sunning decks, Easy River water ride, wave pool with cascades, lighted tennis courts, health spa (with workout equipment, whirlpool, sauna,...), arcade virtual reality game rooms, nightly shows, snack bars, a number of restaurants, shopping area, bars, ... Many of these attractions are open 24 hours a day and most are suitable for families and children. The negotiated hotel's room rate for conference attendees is very reasonable ($79 + tax) per night (no extra charge for double occupancy) for the duration of the conference. The hotel is within walking distance from most other Las Vegas attractions (major shopping areas, recreational destinations, fine dining and night clubs, free street shows, and more). For the benefit of our international colleagues: the state of Nevada neighbors with the states of California, Oregon, Idaho, Utah, and Arizona. Las Vegas is only a few driving hours away from other major cities and attractions, including: Los Angeles, San Diego, Phoenix, the Grand Canyon, and more. EXHIBITION An exhibit is planned for the duration of the conference. We have reserved 20+ exhibit spaces. Interested parties should contact F. Valafar (address is given below). All exhibitors will be considered to be the co-sponsors of the conference. IMPORTANT DATES March 6, 2000 (Monday): One-page Abstracts or Draft papers (about 4 pages) due April 3, 2000 (Monday): Notification of acceptance May 1, 2000 (Monday): Camera-Ready papers & Preregistration due June 26 - 29, 2000: METMBS'2000 Conference Proposals to organize technical sessions should be submitted as soon as possible. All accepted papers are expected to be presented at the conference. MEMBERS OF PROGRAM & ORGANIZING COMMITTEES The Program Committee is currently being formed. Those interested in joining the Program Committee should e-mail F. Valafar (faramarz@cns.bu.edu ) the following information: Name, affiliation and position, complete mailing address, e-mail address, tel/fax numbers, a short biography together with research interests. OTHER INFORMATION Last year PDPTA, CISST, and IC-AI had research contributions from over 44 countries (over 900 participants from all over the world.) To make this a more complete suite of conferences, we have added METMBS. METMBS will also have a strong international flavor and offers its participants an introduction to a wide range of related interdisciplinary subjects through the other three conferences. CONFERENCE CONTACT: Faramarz Valafar Cognitive and Neural Systems Boston University 677 Beacon Street Boston, MA 02215 Tel: (617) 353-5134 Fax: (617) 353-7755 E-mail: Faramarz@cns.bu.edu From owner-immuno@hgmp.mrc.ac.uk Thu Mar 2 04:50:48 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id D1FA817A78; Thu, 2 Mar 2000 04:50:46 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id EAA27330; Thu, 2 Mar 2000 04:50:44 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id EAA29695; Thu, 2 Mar 2000 04:50:42 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: "W. Fred Shaw" X-Newsgroups: bionet.molbio.hiv,bionet.immunology Subject: THE FAUCI FILES 3( 31): Israeli Diva's HAART Cocktail "Organ Failure" Date: Wed, 01 Mar 2000 20:50:31 -0800 Organization: Frontier GlobalCenter Inc. Lines: 108 Message-ID: Reply-To: fredshaw@primenet.com Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Complaints-To: abuse@globalcenter.net X-Posted-By: @207.218.35.142 (fredshaw) X-Newsreader: Forte Agent 1.7/32.534 To: hiv-molbiol@hgmp.mrc.ac.uk, immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk THE FAUCI FILES 3( 31): Israeli Diva's HAART Cocktail "Organ Failure" March 1, 2000 While NIH/NIAID Director-Dictator Dr. Anthony "Mussolini" Fauci continues to orchestrate his conspiracy of silence regarding the lethality of the HIV/AIDS drug cocktail "standard of care" which he has personally orchestrated, the deaths keep climbing. Here comes Ofra, the Israeli Diva with HIV who died of "organ failure", purported to have been "related to AIDS". Oddly enough, AIDS has NEVER been associated with organ failure, except for those who have used HAART and died of organ failure as well (pick an organ: heart, liver, kidney, adrenal, etc). The Israeli media is promoting the notion: "Ofra died of shame" Unfortunately, HAART cocktail drugs don't kill through fatal exacerbations of shame, they kill by massive metabolic disruption of every tissue and organ system of the body. Meanwhile, Israeli health officials are correctly warning that there IS NO TREATMENT for HIV/AIDS and are calling for emphasis on avoidance. Whose will you, your patents and your corporate activists murder next, Dr. Fauci? Elton John? Crooked Murdering Bastards! W. Fred Shaw Editor, THE FAUCI FILES ======================== Death of Israeli Pop Star Debated By DINA KRAFT .c The Associated Press JERUSALEM (AP) - The death of a popular singer from AIDS, and her efforts to conceal her illness from the public, have sparked a furious public debate here about the right to privacy - and the stigma that some here still attach to the illness. The refrain "Ofra died of shame" reverberated through Israel's newspapers and airwaves today. Haza's reported concealment and the widespread reaction to Monday's story about it in the Haaretz daily have highlighted Israeli attitudes toward the disease. The 41-year-old diva died Wednesday of organ failure. Citing the singer's wish to maintain her privacy, doctors who treated her at Tel Aviv's Tel Hashomer Hospital refused to say what brought on her condition. However, Haaretz reported that she died of complications from AIDS. In an editorial, the paper said there was "no reason to demonize" the disease by keeping it a secret. The editorial called AIDS "a human disease like any other." Doctors and family members maintained their silence, and there was no way to know how long Haza had been seeking treatment or how she might have contracted the disease. But Haza fans, politicians and others across Israel speculated today that if she had not feared negative publicity and had sought treatment sooner, she might not have died. "I think the shame, stigma, and lack of information are what killed her," said Tirza Ariel, widow of another popular Israeli singer. Fewer than 3,000 out of 6 million Israelis carry HIV, the virus that causes AIDS. Despite a recent Health Ministry campaign to increase public awareness, some Israelis still have misconceptions about the disease. AIDS activists lamented Haza's reported decision to keep her disease a secret, suggesting it reinforced the message that the disease is shameful. Others raised the prospect that in a more tolerant environment, Haza could have followed the example of someone like American basketball star Magic Johnson, who retired after his 1991 disclosure that he is HIV-positive but has stayed in the public spotlight and become a campaigner for AIDS education. Some AIDS sufferers said friends and acquaintances surprised them by embracing them even after they had "outed" themselves. "Nobody ran away from me, nobody broke off the connection with me," said Avinoam Frumer. Others insisted there is a price for going public. Haza rose from the slums of Tel Aviv to become Israel's first international pop music star, blending ancient Yemenite Jewish devotional poetry with the sounds of 1980s techno music. Other papers and the electronic media said they also knew Haza had AIDS but did not run the story. Some lawmakers and other observers criticized Haaretz for invading Haza's privacy. Haaretz's editorial cited widespread rumors about the cause of death and Haza's status as a public figure in its decision to publish the report. "The attitude she bore toward the disease influences people, both healthy and infirm," Haaretz wrote. AP-NY-02-29-00 1128EST From owner-immuno@hgmp.mrc.ac.uk Thu Mar 2 11:00:12 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 71D8717A66; Thu, 2 Mar 2000 11:00:09 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id KAA05156 for ; Thu, 2 Mar 2000 10:59:55 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id KAA04057 for immuno-list@hgmp.mrc.ac.uk; Thu, 2 Mar 2000 10:59:54 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: unknown@cam.ac.uk (Shared Mac) X-Newsgroups: bionet.immunology Subject: Boosting protein immunisation lowers Ab response Date: Thu, 02 Mar 2000 12:06:43 +0100 Organization: University of Cambridge Lines: 26 Message-ID: To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk Hello to the denizens of bionet.immunology - I have a quick question. Does anyone know if there are examples in the literature similar to the following observation? Following primary immunisation with a protein antigen (delivered using a novel adjuvant) IgG Ab responses were observed that were significantly higher than the response to Ag delivered in buffer. Following a boost immunisation responses with adjuvant were even higher. Following a second boost immunisation IgG Ab responses in the groups receiving Ag in adjuvant had decreased compared to post-first boost and were then not significantly different from the response in the groups receving Ag in buffer. Responses in the groups receiving buffer increased post-second boost so this effect is not due to some problem with the Ag used in the second boost. Immunisations were s/c in mice. Note also that at a low Ag dose Ab responses increased post-primary, post-first boost and post-second boost for Ag delivered in adjuvant and buffer. Thanks for any pointers - please reply to the group. From owner-immuno@hgmp.mrc.ac.uk Thu Mar 2 15:10:43 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 0064617AF7; Thu, 2 Mar 2000 15:10:37 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id PAA09847 for ; Thu, 2 Mar 2000 15:10:24 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id PAA07333 for immuno-list@hgmp.mrc.ac.uk; Thu, 2 Mar 2000 15:10:20 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: Michael Lang X-Newsgroups: bionet.immunology Subject: Vaccine development Date: Thu, 02 Mar 2000 08:03:00 -0700 Organization: University of Calgary Lines: 4 Message-ID: <38BE82A4.9A8B4ACD@acs.ucalgary.ca> Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Trace: nserve1.acs.ucalgary.ca 952009286 23150 136.159.234.64 (2 Mar 2000 15:01:26 GMT) X-Complaints-To: news@ucalgary.ca X-Mailer: Mozilla 4.7 [en]C-compaq (Win98; I) X-Accept-Language: en To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk I'm putting together a lecture for 3rd year undergrads on the various vaccines and strategies used. Does anyone know a good general reference on vaccine development that may not be over their heads? From owner-immuno@hgmp.mrc.ac.uk Thu Mar 2 17:23:42 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 94D5C17AA3; Thu, 2 Mar 2000 17:23:40 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id RAA27770; Thu, 2 Mar 2000 17:23:37 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id RAA09156; Thu, 2 Mar 2000 17:23:32 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: "W. Fred Shaw" X-Newsgroups: bionet.molbio.hiv,bionet.immunology Subject: Patient X, Walking Corpse (was Re: Need advice on bleeding and low platelets) Date: Thu, 02 Mar 2000 09:22:53 -0800 Organization: Frontier GlobalCenter Inc. Lines: 136 Message-ID: <2p8tbsos7o07fc3lt9ivpq4g70kaug1dp2@4ax.com> Reply-To: fredshaw@primenet.com Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Complaints-To: abuse@globalcenter.net X-Posted-By: @207.218.35.155 (fredshaw) X-Newsreader: Forte Agent 1.7/32.534 X-No-Archive: yes To: hiv-molbiol@hgmp.mrc.ac.uk, immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk Patient X, Walking Corpse (was Re: Need advice on bleeding and low platelets) While it is not my intention to offend, abuse nor harass those who are ill, I have found that being nice in these public forums doesn't get the point across when dealing with irrational systems of medical superstition and those who obey them as if they were the religion du jour. Since this post was published in this public forum, I post this as a warning to all others, not necessarily the author of the original post, whose email address has been omitted. fred On Thu, 02 Mar 2000 02:16:07 GMT, in <38bdcb5d.41293435@news.mindspring.com> Patient X wrote on misc.health.aids: >I would appreciate any information on the problem of (apparenly) HIV >induced low-platelet count. I'm currently on a hydroxyurea + DDI >combo, which shouldn't be causing the problem Excuse me? You are taking 2 of perhaps the most toxic drugs in the pharmacopeia that are NOTORIOUS for suppression of the bone marrow and other critically functional areas of the immune response. Anemia, platelet anomalies, high cholesterol and heart disease aren't something to trifle with, now are they? H-E-L-L-O, wake up and smell the fucking coffee! > and I've been in good, stable health for most of fourteen > years of being positive Well you aren't anymore, now are you? If you have been in "good, stable health for most of fourteen years", then why the fuck are you using cancer chemo drugs? Let this be a lesson for others who believe in excellent health and everlasting life through superstitions about cancer chemotherapy being "good" for viral diseases of immune suppression! > and (my) other blood values ... are good: > vl undetectable, t4s in mid 400s, etc. This certainly demonstrates the uselessness of these chemo-manipulated lab values that have NOTHING to do with a better outlook for you since you are using drugs which render these lab values invalid in the first place. Fact is, nearly everyone who is dropping dead has similar, if not "better" lab values than yours (undoubtedly, including the dead Israeli Diva who suffered "organ failure" on these cocktail poisons). > I'm currently having a problem with ongoing posterior nasal bleeding, You aren't the only one on these drugs to report this symptom. Others report intestinal bleeding too. Unfortunately, the blood source is so high in the intestinal tract that the doctor's hemoccult stool test can't pinpoint the source of the bleeding. Have you considered eliminating the drugs from your diet for a couple of weeks/months to see if your problems go away, or are you intent on becoming another AIDS Martyr for the "betterment of science and mankind" as so many other dead idiots have claimed for their suicidal mission ? > and although the docs have not yet been able to tell exactly > where it's coming from or what's causing it (I'm scheduled for a CAT scan) The doctors are looking for a focal point, so believe me, they will probably "invent one" from the CAT scan (you have no way to know if they are bullshitting you or not, but they need to shut you up long enough for your "life-saving" treatment to do its magic and kill you). You also won't be the first to submit to recommendations for nasal surgery. Someone I know in San Francisco had this same problem, got the CAT scan and submitted to the surgery. He almost bled to death on the operating table a couple of months ago. What's worse, his sinus symptoms are much worse and he has progressed to other complications require even more medical interventions. He didn't heed the warnings. Neither will you. You have both been brainwashed to worship the words of wisdom of the quacks in white coats. > they're suggesting intravenous immune globulin treatment. This, of course, will be the doctor's final act of murder. Did you realize that this is EXACTLY THE THING NOT TO DO, or do you intend to get it over with as soon as possible? Immune globulin "treatments" are nothing more than "food for virus". The virus (and most viruses, not just HIV) will replicate like mad as the Ig promotes B cell activation. If you don't get sick, go blind or die from a viral breakthrough of one sort or another, it won't be long before you get one of the new and improved lymphomas that have only been seen in those using these cancer drugs. So there you have it. Like it or not, you've been warned. Follow your doctor's recommendations and you won't be the first to find my words and warnings to be prophetic. Good luck. fred [NOTE: For further details, search Deja.com for "THE FAUCI FILES"] ---- Full text of a walking corpse: >I would appreciate any information on the problem of (apparenly) HIV >induced low-platelet count. I'm currently on a hydroxyurea + DDI >combo, which shouldn't be causing the problem, and all other blood >values (at least the major ones I tend to pay attention to) are good: >vl undetectable, t4s in mid 400s, etc., and I've been in good, stable >health for most of fourteen years of being positive. I'm currently >having a problem with ongoing posterior nasal bleeding, and although >the docs have not yet been able to tell exactly where it's coming from >or what's causing it (I'm scheduled for a CAT scan), they're >suggesting intravenous immune globulin treatment. Beyond the >unpleasant side effects I've read about associated with IVIG, I'm >wondering if there's anything less dramatic that might help? I just >came across an article from AIDS Treatment News (4/4/97) that said >that thiotic acid has been thought by some researchers to lower >platelets, and I've been taking 500mg/day of this for several years. >Has anyone else heard of this connection? Thanks in advance for any >infomation! > >Patient X From owner-immuno@hgmp.mrc.ac.uk Thu Mar 2 17:44:21 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 9687B17A61; Thu, 2 Mar 2000 17:44:20 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id RAA29693 for ; Thu, 2 Mar 2000 17:44:17 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id RAA09404 for immuno-list@hgmp.mrc.ac.uk; Thu, 2 Mar 2000 17:44:16 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: "Joe Chandler" X-Newsgroups: bionet.immunology References: Subject: Re: Boosting protein immunisation lowers Ab response Lines: 9 X-Priority: 3 X-MSMail-Priority: Normal X-Newsreader: Microsoft Outlook Express 5.00.2615.200 X-MimeOLE: Produced By Microsoft MimeOLE V5.00.2615.200 Message-ID: Date: Thu, 2 Mar 2000 08:55:42 -0800 X-Complaints-To: abuse@rr.com X-Trace: newsr1.maine.rr.com 952005400 24.93.156.247 (Thu, 02 Mar 2000 08:56:40 EDT) Organization: RoadRunner Portland, Maine To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk Here is a thought. What was the time frame between the second two boosts? If it was less than three weeks, it is possible that the amount of circulating antigen-specific Ig was high enough to form antigen-antibody complexes clearing most of your immunogen out of the system. This would results in a reducing the actual amount of immunogen left to stimulate the immune system to quite a bit less than you might expect. From owner-immuno@hgmp.mrc.ac.uk Thu Mar 2 18:12:42 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 8519017B3A; Thu, 2 Mar 2000 18:12:41 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id SAA02328; Thu, 2 Mar 2000 18:12:38 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id SAA09667; Thu, 2 Mar 2000 18:12:36 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: "W. Fred Shaw" X-Newsgroups: bionet.molbio.hiv,bionet.immunology Subject: THE FAUCI FILES, 3( 32): Pantaleo: HAART Cocktail Trashes Critical CD8 Immunity Date: Thu, 02 Mar 2000 10:11:57 -0800 Organization: Frontier GlobalCenter Inc. Lines: 214 Message-ID: <8nbtbsktuj7j4b25b8h05nj26rahg6k172@4ax.com> Reply-To: fredshaw@primenet.com Mime-Version: 1.0 Content-Type: text/plain; charset=ISO-8859-1 Content-Transfer-Encoding: 8bit X-Complaints-To: abuse@globalcenter.net X-Posted-By: @207.218.35.155 (fredshaw) X-Newsreader: Forte Agent 1.7/32.534 X-No-Archive: yes To: hiv-molbiol@hgmp.mrc.ac.uk, immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk THE FAUCI FILES, 3( 32): Pantaleo: HAART Cocktail Trashes Critical CD8 Immunity March 2, 2000 As previously revealed by THE FAUCI FILES and now confirmed by Pantaleo et al in the journal Blood (3/1/00, Soudeyns et al.), who concludes that the HAART (HIV cocktail drugs) globally reduces HIV-specific CD8 CTLs and suppresses HIV-1 replication in CD4+ T cells, but does not control HIV infection in tissue macrophages and dendritic cells. In other words, HAART cocktail drugs are not "life savers" at all. To the contrary, they are capable of causing the collapse of life-critical immune protection directly. Hence death-by-HAART. Interestingly, Pantaleo once worked under Dr. Anthony "Mussolini" Fauci at the NIH NIAID Institute, but left the little Mussolini behind to return to conduct his research in Europe. W. Fred Shaw, Editor, THE FAUCI FILES --- The following contribution is from Billi Goldberg: According to Schrager and D'Souza (1998), macrophages are reservoirs of HIV during all phases of disease progression. According to Li et al. (1999), HIV-infected macrophages significantly increase their replicative capacity during advanced disease. Since HAART eliminates cytotoxic/suppressive CD8 CTLs and cannot control active HIV replication in infected macrophages (and/or dendritic cells), there is a distinct possibility that disease progression will continue unabated during "successful" antiretroviral therapy. As concerns the importance of these CD8 CTLs globally reduced by HAART, Soudeyns et al. (Pantaleo is senior author) state: "Acute or primary infection with human immunodeficiency virus type 1 (HIV-1) is characterized by transient high-level viremia, which decreases significantly upon the emergence of the host virus-specific immune response. Particularly effective in the control of primary as well as chronic HIV-1 viremia is the cellular immune response mediated by HIV-specific CD8+ cytotoxic T lymphocytes (CTLs). The authors clearly admit that there is a problem: "Furthermore, similar to what occurs in chronic infection, the global reduction of CD8+ T-cell oligoclonality induced by HAART during primary infection is associated with a progressive reduction in the frequency of circulating HIV-specific CTL precursors and/or effectors. Therefore, it is conceivable that potentiation and long-term maintenance of a diversified HIV-specific CTL repertoire during antiretroviral treatment may require the development of therapeutic vaccine strategies to achieve effective immune-mediated control of HIV replication." Supporting article excerpts: Dr. Guiseppe Pantaleo has reported that HAART does not control HIV replication in tissue macrophages and dendritic cells (Nature Medicine 1997 May; 3(5): 483-486). He states: "A likely scenario is that antiviral therapy may effectively control active virus replication in the pool of high replicating virus cells (that is, CD4+ T cells), and not in the pool of low replicating virus cells, that is, tissue macrophages and/or dendritic cells, which account for the residual (<1%) virus production. Therefore, the pool of low replicating virus cells seems to be mostly refractory to the potent antiviral drugs." In 1998, NIAID's Schrager and D'Souza stated: "Reservoirs of HIV-1 have been identified that represent major impediments to eradication. Conceptually, there are 2 types of sanctuaries for HIV-1, cellular and anatomical. Cellular sanctuaries may include latent CD4+ T cells containing integrated HIV-1 provirus; macrophages, which may express HIV-1 for prolonged periods; and follicular dendritic cells, which may hold infectious HIV-1 on their surfaces for indeterminate lengths of time." The authors also state: "Macrophages may play important roles in abetting HIV-1 infection throughout the disease process, from soon after initial mucosal exposure to the final stages. Human immunodeficiency virus 1 infection of macrophages can be productive but noncytopathic, permitting macrophages to serve as long-lived sources of HIV production. Throughout the course of HIV infection, macrophages have been implicated in carrying virus across the blood-brain barrier and establishing and maintaining HIV infection within the central nervous system (CNS), probably the most important anatomical HIV reservoir. During latter stages of HIV infection, when the CD4+ T-cell population is largely depleted, macrophages may be a key source of de novo HIV replication." As concerns the importance of macrophages during disease progression, Li et al. (1999) state: "However, this study also shows a marked and significant increase in replication as well as tropism for MDM [monocyte-derived macrophages] and monocytes by HIV-1 strains isolated from blood at the advanced stages compared with the early stages of HIV infection." ============================= Soudeyns H, Campi G, Rizzardi GP, Lenge C, Demarest JF, Tambussi G, Lazzarin A, Kaufmann D, Casorati G, Corey L, Pantaleo G. Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. Blood 2000 Mar 1;95(5):1743-1751 Laboratory of AIDS Immunopathogenesis, Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Unit of Immunochemistry, DIBIT, and the Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; Duke University Medical Center, Center for AIDS Research, Durham, NC; Fred Hutchinson Cancer Research Center, Seattle, WA 98105. E-mail: giuseppe.pantaleo@chuv.hospvd.ch Abstract: Major T-cell receptor beta chain variable region (TCRBV) repertoire perturbations are temporally associated with the down-regulation of viremia during primary human immunodeficiency virus (HIV) infection and with oligoclonal expansion and clonal exhaustion of HIV-specific cytotoxic T lymphocytes (CTLs). To determine whether initiation of antiretroviral therapy (ART) or highly active antiretroviral therapy (HAART) during primary infection influences the dynamics of T-cell-mediated immune responses, the TCRBV repertoire was analyzed by semiquantitative polymerase chain reaction in serial blood samples obtained from 11 untreated and 11 ART-treated patients. Repertoire variations were evaluated longitudinally. Stabilization of the TCRBV repertoire was more consistently observed in treated as compared with untreated patients. Furthermore, the extent and the rapidity of stabilization were significantly different in treated versus untreated patients. TCRBV repertoire stabilization was positively correlated with the slope of HIV viremia in the treated group, suggesting an association between repertoire stabilization and virologic response to treatment. To test whether stabilization was associated with variations in the clonal complexity of T-cell populations, T-cell receptor (TCR) heteroduplex mobility shift assays (HMAs) were performed on sequential samples from 4 HAART-treated subjects. Densitometric analysis of HMA profiles showed a reduction in the number of TCR clonotypes in most TCRBV families and a significant decrease in the total number of clonotypes following 7 months of HAART. Furthermore, a biphasic decline in HIV-specific but not heterologous CTL clones was observed. This indicates that ART leads to a global reduction of CD8(+) T-cell oligoclonality and significantly modulates the mobilization of HIV-specific CTL during primary infection. ============================= Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998 Jul 1;280(1):67-71 Epidemiology Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA. LS14M@nih.gov Abstract: The eradication of human immunodeficiency virus 1 (HIV-1) from infected persons is the ultimate goal of HIV therapeutic interventions. Great strides have been made in developing potent antiretroviral regimens that greatly suppress HIV-1 replication. Despite these therapeutic advances, major obstacles remain to eradicating HIV-1. Reservoirs of HIV-1 have been identified that represent major impediments to eradication. Conceptually, there are 2 types of sanctuaries for HIV-1, cellular and anatomical. Cellular sanctuaries may include latent CD4+ T cells containing integrated HIV-1 provirus; macrophages, which may express HIV-1 for prolonged periods; and follicular dendritic cells, which may hold infectious HIV-1 on their surfaces for indeterminate lengths of time. The key anatomical reservoir for HIV-1 appears to be the central nervous system. An understanding of the nature of HIV within these reservoirs is critical to devising strategies to hasten viral eradication. ============================= Li S, Juarez J, Alali M, Dwyer D, Collman R, Cunningham A, Naif HM. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J Virol 1999 Dec;73(12):9741-55 Centre for Virus Research, Westmead Millennium Institute, National Centre for HIV Virology Research, Westmead, NSW 2145, Australia. Email: Hassann@westgate.wh.usyd.edu.au (Hassann Naif) Abstract: Viral phenotype, tropism, coreceptor usage, and envelope gene diversity were examined in blood isolates collected from 27 individuals at different stages of human immunodeficiency virus type 1 (HIV-1) disease and tissue derived isolates from 10 individuals with AIDS. The majority (89%) of blood and all tissue HIV-1 isolates from all stages of infection were non-syncytium inducing and macrophage (M) tropic. Tropism and productive infection by HIV isolates in both monocytes and monocyte-derived macrophages (MDM) increased in advanced disease (HIV tropism for monocytes, 1 of 6 from categories I and II versus 11 of 21 [P = 0.05] from category IV and II [CD4 < 250]; and high-level replication in MDM, 1 of 6 from categories I and II versus 16 of 21 from categories IV and II [P = 0. 015]). There was a high level of replication of blood and tissue isolates in T lymphocytes without restriction at any stage. Overall, the level of replication in MDM was 5- to 10-fold greater than in monocytes, with restriction in the latter occurring mainly at entry and later stages of replication. Only three blood isolates were identified as syncytium inducing, and all had a dualtropic phenotype. There was a significant increase of HIV envelope gene diversity, as shown by a heteroduplex mobility assay, in advanced disease; this may partly underlie the increase of HIV replication in MDM. Unlike blood isolates (even those from patients with advanced disease), tissue isolates displayed greater similarities (90%) in productive infection between MDM and monocytes. The majority (87%) of all isolates, including those from patients with advanced disease, used CCR5, and only 5 of 37 isolates showed expanded coreceptor usage. These results indicate that in the late stage of disease with increasing viral load and diversity, CCR5 utilization and M-tropism persist in blood and tissue and the replicative ability in macrophages increases. This suggests that these characteristics are advantageous to HIV and are important to disease progression. From owner-immuno@hgmp.mrc.ac.uk Thu Mar 2 20:00:51 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 3C1C617A68; Thu, 2 Mar 2000 20:00:50 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id UAA09973; Thu, 2 Mar 2000 20:00:48 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id UAA11002; Thu, 2 Mar 2000 20:00:47 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: "W. Fred Shaw" X-Newsgroups: bionet.molbio.hiv,bionet.immunology Subject: THE FAUCI FILES, 3( 33): NEJM Admits Illegal Falsifications, Fauci-Style Date: Thu, 02 Mar 2000 12:00:20 -0800 Organization: Frontier GlobalCenter Inc. Lines: 123 Message-ID: Reply-To: fredshaw@primenet.com Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Complaints-To: abuse@globalcenter.net X-Posted-By: @207.218.34.235 (fredshaw) X-Newsreader: Forte Agent 1.7/32.534 To: hiv-molbiol@hgmp.mrc.ac.uk, immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk THE FAUCI FILES, 3( 33): NEJM Admits Illegal Falsifications, Fauci-Style March 2, 2000 While Byzantine politics has consumed the infectious disease medical establishment under NIH/NIAID Direktor-Dictator Dr. Anthony "Mussolini" Fauci, it appears that the takeover of medical institutions by the pharmaceutical industry has even reached the ivory tower of the esteemed New England Journal of Medicine. "In an extraordinary apology to readers, the prestigious The New England Journal of Medicine admitted violating its financial conflict-of-interest policy 19 times over the past 3 years in its selection of doctors to review new drug treatments." The New England Journal of Medicine has been added to the "corporate sponsorship" list after it was busted for publishing articles by "researchers" who have been bought and paid for by various pharmaceutical interests: "The internal review was prompted by a news report..." Dr. Marcia Angell, NEJM editor in chief offers a false apology in her too-little, too-late response: "It was carelessness on our part" and, the confession of Murder Inc.: "Angell said the stricter policy for review articles is difficult to maintain because "there's so much connection between academia and the private sector now." Naturally, one of the "careless" articles in question had to do with the HIV Haart Cocktail Drug hoax, which has been entirely fueled by the phony hype surrounding similar drug company exploits in the journal arena. This partial list of falsified journal-article purveyors is a bit too familiar on the HIV/AIDS cocktail hype-circuit: "... (from) biotech companies to pharmaceutical giants like Bristol-Myers Squibb, Merck & Co., Pharmacia & Upjohn, and Wyeth-Ayerst." Crooked Murdering Bastards! W. Fred Shaw, Editor ==================== NEJM Apologizes for Conflicts of Interest Editor in Chief Faults Herself, Staff for 'Carelessness' By Linda A. Johnson Associated Press Writer Feb. 23, 2000 -- In an extraordinary apology to readers, the prestigious The New England Journal of Medicine admitted violating its financial conflict-of-interest policy 19 times over the past 3 years in its selection of doctors to review new drug treatments. The Boston-based weekly journal, considered one of the world's premier medical publications, disclosed in Thursday's issue that it let doctors who had financial ties to the drug makers write the articles. "It was carelessness on our part," Dr. Marcia Angell, editor in chief since September, said in an interview. The internal review was prompted by a news report about one such violation last fall. It found 18 additional instances since January 1997. The violations involve the journal's "Drug Therapy" feature, a series of reviews of the latest drug treatments for particular illnesses. In each case, the journal failed to disqualify authors even though they had revealed their financial ties up front, Angell said. Angell said the journal solicits authors to write the reviews but is supposed to bar those that have directly or indirectly received "major research support" or payment as a consultant from companies that make drugs prominently discussed in those articles. The "Drug Therapy" series is overseen by an outside editor, Dr. Alistair J.J. Wood, a pharmacology professor at Vanderbilt University in Nashville, Tenn. Angell said Wood disqualified authors who personally received significant research funding from the maker of drugs discussed prominently in an article but failed to disqualify authors whose institutions received such grants or authors who served as consultants to the drug companies. She said some in-house editors knew of the practice and overlooked it. She said she suspects there were violations before 1997, too, but the in-house review went back only 3 years. Wood has been editing the series for about a decade. In a letter to readers, Angell apologized for the lapse and said steps have been taken to ensure against any recurrence. She said no action was taken against Wood. He and a deputy editor who helps edit the series also signed the letter. The letter listed the 18 newly uncovered articles along with the drug makers, which ranged from little-known biotech companies to pharmaceutical giants like Bristol-Myers Squibb, Merck & Co., Pharmacia & Upjohn, and Wyeth-Ayerst. The journal regularly publishes original, unsolicited articles on clinical trials of particular drugs written by academic scientists who have received major research funding from a drug manufacturer involved. In those cases, the article notes those funding sources at the end. Angell said the stricter policy for review articles is difficult to maintain because "there's so much connection between academia and the private sector now." --- From owner-immuno@hgmp.mrc.ac.uk Fri Mar 3 11:26:35 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 2350417A43; Fri, 3 Mar 2000 11:26:33 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id LAA20621 for ; Fri, 3 Mar 2000 11:26:31 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id LAA00586 for immuno-list@hgmp.mrc.ac.uk; Fri, 3 Mar 2000 11:26:30 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: Mike Clark X-Newsgroups: bionet.immunology Subject: Re: Boosting protein immunisation lowers Ab response Date: Fri, 3 Mar 2000 11:26:59 +0000 Organization: Cambridge University, Department of Pathology. Lines: 47 Message-ID: References: Mime-Version: 1.0 Content-Type: TEXT/PLAIN; CHARSET=US-ASCII X-Newsreader: ANT RISCOS Marcel [ver 1.53] To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk In article , Shared Mac wrote: > Hello to the denizens of bionet.immunology - I have a quick question. > > Does anyone know if there are examples in the literature similar to the > following observation? > > Following primary immunisation with a protein antigen (delivered using a > novel adjuvant) IgG Ab responses were observed that were significantly > higher than the response to Ag delivered in buffer. > > Following a boost immunisation responses with adjuvant were even higher. > > Following a second boost immunisation IgG Ab responses in the groups > receiving Ag in adjuvant had decreased compared to post-first boost and > were then not significantly different from the response in the groups > receving Ag in buffer. > Responses in the groups receiving buffer increased post-second boost so > this effect is not due to some problem with the Ag used in the second > boost. > > Immunisations were s/c in mice. > > Note also that at a low Ag dose Ab responses increased post-primary, > post-first boost and post-second boost for Ag delivered in adjuvant and > buffer. > > Thanks for any pointers - please reply to the group. > You don't give details of timing or of the assay used for Ig. I can think of two things that you should check for. [1] One is that you might be forcing the immune reponse to class switch to a class or sub-class whihc you are not detecting in your assays. [2] You might be forcing the system into a state of tolerance or suppression for antibody responses to your antigen. This is more likely with higher doses of antigen given more frequently. Mike -- o/ \\ // || ,_ o M.R. Clark, PhD. Division of Immunology <\__,\\ // __o || / /\, Cambridge University, Dept. Pathology "> || _`\<,_ // \\ \> | Tennis Court Rd., Cambridge CB2 1QP ` || (_)/ (_) // \\ \_ Tel.+44 1223 333705 Fax.+44 1223 333875 From owner-immuno@hgmp.mrc.ac.uk Fri Mar 3 13:21:36 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 1DD0817A43; Fri, 3 Mar 2000 13:21:35 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id NAA01940 for ; Fri, 3 Mar 2000 13:21:34 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id NAA01985 for immuno-list@hgmp.mrc.ac.uk; Fri, 3 Mar 2000 13:21:32 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: "Mark Fowler" X-Newsgroups: bionet.immunology Subject: Human Beta-Defensins. Date: Fri, 3 Mar 2000 13:16:20 -0800 Organization: Southampton University Lines: 8 Message-ID: <89odu4$2og$1@chestnut.sucs.soton.ac.uk> X-Trace: chestnut.sucs.soton.ac.uk 952089348 2832 152.78.4.102 (3 Mar 2000 13:15:48 GMT) X-Complaints-To: newsmaster@soton.ac.uk X-Priority: 3 X-MSMail-Priority: Normal X-Newsreader: Microsoft Outlook Express 5.00.2314.1300 X-MimeOLE: Produced By Microsoft MimeOLE V5.00.2314.1300 To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk Does anyone know where I can order HBD1 and HBD2 antibodies from, someone indicated that they are now available commercially. Any help appreciated. Mark Fowler mif@soton.ac.uk From owner-immuno@hgmp.mrc.ac.uk Fri Mar 3 19:20:35 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id C936B17A6E; Fri, 3 Mar 2000 19:20:34 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id TAA22582 for ; Fri, 3 Mar 2000 19:20:31 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id TAA06568 for immuno-list@hgmp.mrc.ac.uk; Fri, 3 Mar 2000 19:20:30 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: Nieves Gonzalez Ramon X-Newsgroups: bionet.immunology Subject: Search on Medline Date: Fri, 03 Mar 2000 20:27:32 +0100 Organization: el =?iso-8859-1?Q?pa=EDs?= de los tulipanes Lines: 89 Message-ID: <38C0121C.9AFF2707@wxs.nl> Reply-To: ni.gonzalez.ramon@wxs.nl Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii; x-mac-type="54455854"; x-mac-creator="4D4F5353" Content-Transfer-Encoding: 7bit X-Trace: reader2.wxs.nl 952111136 4949218 195.121.224.212 (3 Mar 2000 19:18:56 GMT) X-Complaints-To: abuse@wxs.nl X-Mailer: Mozilla 4.7 (Macintosh; I; PPC) X-Accept-Language: en,es To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk MEDLINE Several interfaces allow the search on MEDLINE. Not willing to be exhaustive I selected a sample of them: 1) Biomednet search interface. http://www.biomednet.com/db/medline/advanced This one offers a separate help window, independent from the search one and giving brief but accurate info of the capabilities and a friendly interface with menu choice of search fields. a) Near operator for searching words in close proximity to each other. Inside a phrase search, you can use the * to represent the possible occurrence of intervening words. This is also known as ordered proximity searching, as the words must still occur in the same order as they are present in the phrase. e.g. 1 -Drosophila *1 homeotic- searches for the term "Drosophila" followed by "homeotic" with no more than one intervening word. Items retrieved include phrases such as "In Drosophila, most homeotic genes are..." and "Drosophila homeotic genes are usually expressed...". e.g. 2 -acetylation *5 histones- searches for "acetylation" followed by "histones" with no more than 5 intervening words, and will match phrases such as "acetylation of various Xenopus histones". b) Wildcards Two symbols are available * matches any number of characters including none. e.g. sul*ur matches sulphur; sulfur. e.g. catheter* matches catheters; catheterisation; catheterization; catheterise etc. ? matches exactly one character. e.g. sulf?nyl matches sulfonyl or sulfinyl. Using unnecessary wildcards may slow down response time. Consider using stemming instead. c) Stemming allows you to retrieve a group of words having the same word root. For example, when stemming is switched on infection will also match infect, infectious, infecting etc. If the stemming checkbox is checked, stemming will be applied to all query terms. If not, then + can be used after an individual word to indicate that that word should be stemmed. e.g. fluorescence+ and calcium produces around 50% more hits than fluorescence and calcium Stemming is a faster alternative to wildcards, but, as with wildcards, it cannot be used inside phrases. d) Soundex matching If you append the symbol $ to a search term, it will be matched using soundex phonetic matching technology, to include similar sounding words. e.g. stevenson$:au will match 'stevenson', 'stephenson' and 'stephens' The soundex matching algorithm puts very loose constraints on what are regarded as "similar" names, so it is most useful as an additional constraint on an query rather than as a primary search mechanism itself. 2) The new version of PUBMED (launched on the web 4 months ago), with a lot more of improved tools than the precedent one: http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?db=PubMed This new version of PubMed with pull-down menus that display - Field limits, indexes - HISTORY of search queries and combination of them (typing each query as #1, #2 and combining with the Boolean AND; OR ;NOT always in capital letters). - Hyperlinks to the FULL TEXT document. Depending on the publisher the article will be of free access or on subscription. - Allows "saving a search query" in the format of an URL, so that it can be resent to get updates of your frequently used searches. 3) Internet Grateful Med (IGM) searches MEDLINE using the retrieval engine of NLM's PubMed system. http://igm.nlm.nih.gov/ Additionally it contains other Databases: MEDLINE, AIDSLINE, AIDSDRUGS, AIDSTRIALS, BIOETHICSLINE, ChemID, DIRLINE, HealthSTAR, HISTLINE, HSRPROJ, OLDMEDLINE, POPLINE, SDILINE, SPACELINE, TOXLINE. - Also allows "saving a search query" in the format of an URL. Regards From owner-immuno@hgmp.mrc.ac.uk Sat Mar 4 22:34:01 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 1155717AB1; Sat, 4 Mar 2000 22:33:59 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id WAA26660 for ; Sat, 4 Mar 2000 22:33:58 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id WAA12880 for immuno-list@hgmp.mrc.ac.uk; Sat, 4 Mar 2000 22:33:57 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: jwissmille@aol.com (JWissmille) X-Newsgroups: bionet.immunology Subject: BERMUDA TRIANGLE of science-research dollars Lines: 55 X-Admin: news@aol.com Date: 04 Mar 2000 22:33:55 GMT Organization: AOL http://www.aol.com Message-ID: <20000304173355.03475.00000568@ng-bk1.aol.com> To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk [Note: Not only has CDC "misplaced" major funding for CFIDS/CFS research, but admits to diverting funds from hanta virus--and now, in this segment, add Lyme disease into the CDC, or BERMUDA TRIANGLE of science-research dollars.] CDC SCANDAL: Lively exchange at Senate hearing by Roger Burns WASHINGTON, Feb. 29 -- In contrast to a U.S. House of Representatives hearing held earlier this month, today's hearing before a U.S. Senate committee was lively, and was difficult for the official being questioned, Dr. Jeffrey Koplan, Dircetor of the CDC. Several questions were posed to Director Koplan about the CDC's diversion of research funds and the adequacy of that agency's CFS program, but Koplan's routine answers were not accepted by Senator Herbert Reid (D-NV) and subcommittee chairman Senator Arlen Spector (R-PA). Sen. Reid expressed astonishment that a CDC employee had told the Inspector-General that "It's a 'bigger crime' to follow Congress's direction rather than spend money where science dictates", as reported in the Washington Post and in other newspapers around the U.S. Reid said that that was virtually spitting in the eye of Congress, and asked how could the CDC keep such a person on its payroll. Director Koplan said he wasn't familiar with that employee and was unaware that such a statement had been made, so he couldn't respond specifically, but the quote given was antithetical to Koplan's own beliefs. Sen. Reid also said there were new reports that research funds for Lyme disease had also been diverted. Sen. Arlen Spector bore in to Dr. Koplan during his own question period. Spector asked Koplan three times whether he had gotten more information from the Inspector-General's office than just the official report. The Senator further asked whether there were other diseases in addition to hantavirus and CFS that were involved in the diversion of funds, to which Koplan replied no. Spector also asked what disciplinary actions the CDC had taken. At first Koplan responded that there had been a re-assignment of one administrator. But under further questioning by Spector, Koplan later said that the re-assignment had nothing to do with a disciplinary action but was done only because that individual's talents were more useful elsewhere. At the end of the hearing, Spector asked Koplan whether he had determined that false statements had ever been made about the CFS program. At that point, HHS Secretary Shalala intervened and said that the privacy laws which protect government employees prevent Director Koplan from answering that question. After consulting with Secy. Shalala in private, an apparently frustrated Senator Spector said he would defer his question for the moment, but that it would ultimately be answered in public, and if need be there would be an additional Senate hearing. During today's hearing, Sen. Ted Stevens (R-AK) said that he felt this entire issue was likely due to a misunderstanding and that no misstatements were made intentionally by CDC staff. Sen. Stevens outlined the need for improved coordination between the CDC and Congress. From owner-immuno@hgmp.mrc.ac.uk Mon Mar 6 08:18:02 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 3456A17AAB; Mon, 6 Mar 2000 08:18:00 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id IAA22296 for ; Mon, 6 Mar 2000 08:17:47 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id IAA14984 for immuno-list@hgmp.mrc.ac.uk; Mon, 6 Mar 2000 08:17:45 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: dickie Subject: glyconutritionals / how they may help with auto immune disease X-Newsgroups: bionet.immunology Message-ID: <1ca4f2e8.09b62113@usw-ex0110-075.remarq.com> Lines: 9 Bytes: 505 X-Originating-Host: 194.129.108.70 Organization: http://www.remarq.com: The World's Usenet/Discussions Start Here X-Wren-Trace: eD0YMDEobyVubyA2MHwuMGEmIiorLnQnNBExLDEtLWk+InIyPXwhIH8/NnYmdm57ZWV/Y3g7EwwNBURibA== Date: Mon, 06 Mar 2000 01:09:31 -0800 X-Complaints-To: wrenabuse@remarq.com X-Trace: WReNphoon2 952330386 10.0.2.75 (Mon, 06 Mar 2000 00:13:06 PST) To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk Nearly all disease is caused by Immune system dysfunction. Due to stress, high levels of toxins in the air and water, and nutritional deficiencies our immune systems are being compromised. This could be reversable with the help of Glyconutritionals. See website www.glycoscience.com for more information.(richard.horswill@creditlyonnais.co.uk) * Sent from AltaVista http://www.altavista.com Where you can also find related Web Pages, Images, Audios, Videos, News, and Shopping. Smart is Beautiful From owner-immuno@hgmp.mrc.ac.uk Mon Mar 6 19:27:26 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id AD67C17A70; Mon, 6 Mar 2000 19:27:24 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id TAA10596; Mon, 6 Mar 2000 19:27:21 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id TAA23367; Mon, 6 Mar 2000 19:27:20 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: "W. Fred Shaw" X-Newsgroups: bionet.molbio.hiv,bionet.immunology Subject: THE FAUCI FILES, 3( 35): Clerici: HIV Cocktails Shut Down Immune Response ! Date: Mon, 06 Mar 2000 11:27:08 -0800 Organization: Frontier GlobalCenter Inc. Lines: 109 Message-ID: <9k18cskjn8f1ku58tqpe32gjkfvmm8liuu@4ax.com> Reply-To: fredshaw@primenet.com Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Complaints-To: abuse@globalcenter.net X-Posted-By: @207.218.50.191 (fredshaw) X-Newsreader: Forte Agent 1.7/32.534 X-No-Archive: yes To: hiv-molbiol@hgmp.mrc.ac.uk, immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk THE FAUCI FILES, 3( 35): Clerici: HIV Cocktails Shut Down Immune Response ! May 6, 2000 Under the tutelage of NIH/NIAID Director Dr. Anthony "Mussolini" Fauci, the budget-dictating bureaucrat behind HIV/AIDS research disaster in America for the past two decades (the 80's, 90's and now the 00's), let's take a close look at the "pinnacle" of Fauci's "leadership", which we all know is the HIV cocktail "standard of care", otherwise known as HAART (for Highly Active Anti-Retroviral Therapy, which has recently lost it's "HA", and is now smugly called "ART", with a tinge of grim humor). Here are the golden words from the one who is one of Europe's greatest and most ethical HIV/AIDS researcher, Dr. Mario Clerici, who has written the HA-ART epitaph in the January 28, 2000 edition of the AIDS journal, where his team decisively compared the immunological profiles of the HAART-treated with the immunological profiles of antiretroviral-naive patients, both with undetectable viremia: "HAART is associated with weaker HIV-specific and -non-specific immune responses." "Our results show that immune responses are potent in antiretroviral-naive but significantly reduced in HAART-treated patients with undetectable viraemia (< 500 copies/ml)." ". . . T-cell proliferation to HIV-specific and HIV-unrelated antigens is potent in antiretroviral-naive but suppressed in HAART-treated individuals; . . ." As predicted from the outset of THE FAUCI FILES, it looks like the ART Hoax, stripped of its "HA", has reached the end of its Hype Cycle. As to Fauci and his Corporate Activist minions assigned to this newsgroup, this would be a good time to get out of town. Crooked Murdering Bastards! W. Fred Shaw Editor, THE FAUCI FILES By the way, the following article took eight (8) months to be published (from submittal to publication) in a journal which prides itself on the "fast track" publishing of crucial treatment data. Now we understand the nature of the "fast track" litmus test for quick publication: the article MUST NOT contradict a "standard of care" pharmaceutical product. Besides, one wouldn't think the AIDS journal wanted this circulated prior to the recent San Francisco Pharmaceutical HAART Hype-n-Schlock Conference. Unlike the vast majority of the important AIDS journal articles, good luck finding this one on the net as it is conspicuous by its absence. ======================= Clerici M,* Seminari E, Suter F, Castelli F, Pan A, Biasin M, Colombo F, Trabattoni D, Maggiolo F, Carosi G, Maserti R (for the Master Group). Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia. AIDS 2000 Jan 28; 14:109-116. *Cattedra di Immunologia, Universita degli Studi di Milano, Via Venezian, 1, 20122 Milan, Italy. Tel: +390238210354; fax: +390238210350; e-mail: mago@mailserver.unimi.it Background: Suppression of human immunodeficiency virus (HIV) replication can be obtained in chronically infected individuals by highly active antiretroviral therapy (HAART) and can also be observed in antiretroviral-naive patients. The immunological correlates of these two situations were examined. Design and methods: Cross-sectional study involving 32 HIV-infected patients with undetectable HIV plasma viraemia (< 500 copies/ml) and either antiretroviral-naive (n = 14) or undergoing HAART therapy with two nucleoside reverse transcriptase inhibitors (NRTI) plus one (n = 13) or two (n = 5) protease inhibitors (PI). CD4 counts, disease duration, and CDC clinical stage were comparable between the two groups of individuals. Immune parameters (antigen- and mitogen-stimulated proliferation and cytokine production; cytokine mRNA; beta chemokine production; HIV coreceptors mRNA) were analysed in all patients. Results: Results showed immune profiles to be profoundly different in antiretroviral-naive in comparison with HAART-treated patients. Thus: (1) T-cell proliferation to HIV-specific and HIV-unrelated antigens is potent in antiretroviral-naive but suppressed in HAART-treated individuals; (2) interleukin-(IL)2, IL-12 and interferon gamma (IFNgamma) production is robust in naive patients; and (3) a high CCR5/low CXCR4 pattern of HIV coreceptors-specific mRNA is observed in naive but not in HAART-treated patients. In contrast with these observations, no clear differences were detected when beta chemokine production by either peripheral blood mononuclear cells or purified CD8+ T-cells was analysed. Results from HAART-treated patients undergoing therapy with one PI and two NRTI or two PI and two NRTI were in very close agreement. Conclusions: These data suggest that control over HIV replication can be independently achieved by pharmacological or immunologic means. HAART is associated with weaker HIV-specific and -non-specific immune responses. --- From owner-immuno@hgmp.mrc.ac.uk Mon Mar 6 21:00:19 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id C443C17A5E; Mon, 6 Mar 2000 21:00:18 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id VAA15983 for ; Mon, 6 Mar 2000 21:00:15 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id VAA24449 for immuno-list@hgmp.mrc.ac.uk; Mon, 6 Mar 2000 21:00:14 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: rdara@uoguelph.ca (Rozita Dara) X-Newsgroups: bionet.immunology Subject: Post-doc position in autoimmunity Date: 6 Mar 2000 20:50:03 GMT Organization: University of Guelph Lines: 36 Message-ID: <8a15lr$lb7$1@testinfo.cs.uoguelph.ca> X-Newsreader: TIN [version 1.2 PL2] To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk I am posting this announcement on behalf of Dr. Delovitch. Please address all correspondence directly to the following address: Terry L. Delovitch, Ph.D. del@rri.on.ca Director, Autoimmunity/Diabetes Group The John P. Robarts Research Institute 1400 Western Road London, ON N6G 2V4 Canada Telephone: (519) 663-3972 Facsimile: (519) 663-3847 Postdoctoral Positions in Immunology of Autoimmune Diabetes Applications are invited for two postdoctoral positions available immediately to study: 1) the roles of cytokines, chemokines and their receptors in the immunoregulation of susceptibility to autoimmune diabetes in nonobese diabetic (NOD) mice, and 2) the biochemistry of signaling and apoptosis in anergic NOD T cells. These positions are available in conjunction with a JDF/MRC supported Diabetes Centre of Excellence. Highly motivated candidates should have a recent Ph.D. or M.D./Ph.D. in immunology or related discipline, and be familiar with techniques in cellular/molecularimmunology, molecular biology, animal models of autoimmunity and gene transfer. Please email or fax CV, statement of research interests, and names and addresses of three references. From owner-immuno@hgmp.mrc.ac.uk Tue Mar 7 11:40:34 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id CE17817A8F; Tue, 7 Mar 2000 11:40:32 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id LAA27333 for ; Tue, 7 Mar 2000 11:40:27 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id LAA13428 for immuno-list@hgmp.mrc.ac.uk; Tue, 7 Mar 2000 11:40:26 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: "John H." X-Newsgroups: bionet.immunology Subject: Re: glyconutritionals / how they may help with auto immune disease Date: Tue, 7 Mar 2000 20:52:08 +1000 Organization: World Wire Pty. Ltd. Lines: 30 Message-ID: <8a2nii$1k66$5@news1.wire.net.au> References: <1ca4f2e8.09b62113@usw-ex0110-075.remarq.com> Reply-To: "John H." X-Trace: news1.wire.net.au 952426898 53446 203.25.204.130 (7 Mar 2000 11:01:38 GMT) X-Complaints-To: usenet@news1.wire.net.au X-Priority: 3 X-MSMail-Priority: Normal X-Newsreader: Microsoft Outlook Express 5.00.2014.211 X-MimeOLE: Produced By Microsoft MimeOLE V5.00.2014.211 To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk dickie wrote in message news:1ca4f2e8.09b62113@usw-ex0110-075.remarq.com... > Nearly all disease is caused by Immune system dysfunction. Where on earth did you get this notion? > Due to stress, high levels of toxins in the air and water, > and nutritional deficiencies our immune systems are being > compromised. This could be reversable with the help of > Glyconutritionals. See website www.glycoscience.com for > more information.(richard.horswill@creditlyonnais.co.uk) > If toxins alone are the problem then that would be so easy to confirm ... . It hasn't been. Do it, then come back with your argument. John H. > * Sent from AltaVista http://www.altavista.com Where you can also find related Web Pages, Images, Audios, Videos, News, and Shopping. Smart is Beautiful From owner-immuno@hgmp.mrc.ac.uk Tue Mar 7 15:58:10 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 84B6E17ABB; Tue, 7 Mar 2000 15:58:09 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id PAA25581 for ; Tue, 7 Mar 2000 15:58:06 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id PAA16680 for immuno-list@hgmp.mrc.ac.uk; Tue, 7 Mar 2000 15:58:05 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: weigt@ita.fhg.de (Henning Weigt) X-Newsgroups: bionet.immunology Subject: CCR7 antibody Date: Wed, 08 Mar 2000 00:50:21 GMT Organization: Fraunhofer Gesellschaft Lines: 7 Message-ID: <38c5a32b.6276719@news.fhg.de> X-Newsreader: Forte Free Agent 1.11/16.235 To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk Hello, does anybody know about antibodys against human CCR7 (flow cytometry use)? I would appreciate any hints, H. Weigt From owner-immuno@hgmp.mrc.ac.uk Tue Mar 7 20:49:46 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 8937917AFD; Tue, 7 Mar 2000 20:49:45 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id UAA22990 for ; Tue, 7 Mar 2000 20:49:40 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id UAA20216 for immuno-list@hgmp.mrc.ac.uk; Tue, 7 Mar 2000 20:49:39 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: jwissmille@aol.com (JWissmille) X-Newsgroups: bionet.immunology Subject: Tick borne diseases conference Lines: 269 X-Admin: news@aol.com Date: 07 Mar 2000 20:49:28 GMT Organization: AOL http://www.aol.com Mime-Version: 1.0 Content-Type: text/plain; charset=utf-8 Content-Transfer-Encoding: 8bit Message-ID: <20000307154928.02591.00000610@ng-fp1.aol.com> To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk ou can still sign-up and get a room at the hotel!! ******** 13th International Conference on Lyme Disease and **************** ***************Other Tick-Borne Disorders *********************** ************* Clinical Management & Research Update ************* Jointly Sponsored by The College of Physicians and Surgeons of Columbia Universityand the Lyme Disease Foundation Keynote Speakers: Attorney General Richard Blumenthal - Protecting the Public Health Willy Burgdorfer, PhD, MD (hon) - Discoverer of the pathogen causing LD Senator Christopher Dodd - United States Senate - CT March 25 & 26, 2000 Farmington Marriott, Farmington, CT Place: Hartford Marriott, Farmington, CT 800-228-9290 $79 single/double. Reserve your room now. The hotel is expected to sell-out! Rate applies 3/23 - 3/27 - for those who want a side trip, maybe to Lyme, CT! Travel: Huntington Hay Travel 800-783-9783. Bradley is the closest airport with shuttle service to the hotel. However, there is also a shuttle service from LaGuardia and Kennedy airports (3 hr ride). ****************** PROGRAM AGENDA ******* ******** FRIDAY MARCH 24, 2000 • Light Reception and Registration 7 - 10 pm ***** SATURDAY MARCH 25, 2000 • Registration 7- 9am • Program 8am - 5:30pm • Reception 7-10pm Presenters: • Keynote: Richard Blumenthal, Attorney General of Connecticut • West Nile Virus: Epicenter to epidemic and what to expect in 2000 Tracey McNamara, DVM, Diplomate ACVP National Wildlife Conservation / Bronx Zoo • West Nile in Connecticut John Anderson, PhD Connecticut Agricultural Experiment Station • Overview of human ehrlichioses and Rocky Mountain spotted fever in the US Christopher Paddock, MD Centers for Disease Control and Prevention • Babesiosis Peter Krause, MD University of Connecticut School of Medicine • Prevalence of infection in ticks submitted to the human test kit program of the U.S. Army Center for Health Promotion and Preventive Medicine Ellen Stromdahl, MS US Army Center for Health Promotion and Preventive Medicine • Analysis of Southern Borrelia Angela James, PhD Centers for Disease Control and Prevention • Coinfections Louis Magnarelli, PhD Connecticut Agricultural Experiment Station • Preliminary in vitro and in vivo findings of hyperbaric oxygen treatment in experimental Bb infection Charles Pavia, PhD NY Medical College School of Medicine, NYCOM Microbiology and Immunodiagnostic Laboratory of NYIT • Immunity against host-adapted B. burgdorferi in the rabbit James Miller, PhD UCLA School of Medicine • Immunologic aspects of Vlse, a B. burgdorferi antigenic variation protein Steve Norris, PhD University of Texas Medical School • An immunodominant peptide of B. burgdorferi Vlse: Role in diagnosis & pathogenesis Mario Philipp, PhD Tulane University School of Medicine • Antibiotic treatment of Lyme borreliosis: A review of results with dogs Rheinhard Straubinger, DVM, PhD Cornell University School of Veterinary Medicine • A Bb repetitive antigen that confers protection against experimental LD Jon Skare, PhD Texas A & M University System Health Science Center • Use of the borreliacidal assay in the serodiagnosis of Lyme disease Ronald Schell, PhD University of Wisconsin School of Medicine • Lyme neuroborreliosis - The role of PCR and culture in the diagnosis and in the confirmation of relapse after antibiotic treatment Jarmo Oksi, MD, PhD Turku University Central Hospital, Department of Medicine, Finland • Laboratory Testing Panel Mark Golightly, MD SUNY at Stony Brook School of Medicine Eli Mordechai, PhD Medical Diagnostic Laboratories Ronald Schell, PhD University of Wisconsin School of Medicine Jyotsna Shah, PhD Igenex Laboratories Richard Tilton, PhD BBI Clinicial Laboratories Steven Schutzer, MD University of Medicine and Dentistry of New Jersey SUNDAY MARCH 26, 2000 Registration 7-8am (CME Sign-in) Program 8AM - 5PM Presenters: • Keynote Willy Burgdorfer, PhD, MD National Institutes of Health • Characterization of an immune evasion system in the Lyme disease spirochetes Richard Marconi, PhD Medical College of Virginia • Matrix metalloproteinases in Lyme disease George Perides, PhD Beth Israel Deaconess Medical Center (Harvard) • Interleukin-10 regulation during acute Lyme arthritis in dogs Reinhard Straubinger, DVM, PhD Cornell University School of Veterinary Medicine • T-cell response Adriana Marques, MD National Institutes of Health • Protection against tick-transmitted disease in dogs vaccinated with a multiantigenic vaccine Alan Frey, PhD New York University School of Medicine • Update on the SKB OspA vaccine Dennis Parenti, MD SmithKline Beecham Biologicals • Atypical EM and acute Lyme disease Edwin Masters, MD Regional Primary Care Physicians • Neurologic Lyme disease in adults Patricia Coyle, MD SUNY at Stony Brook School of Medicine • Neurologic Lyme disease in children and adolescents Dorothy Pietrucha, MD, FAAP Jersey Shore Medical Center, Meridan Health System • Cognitive deficits in children and the public health/educational implications Marian Rissenberg, MD Columbia University School of Medicine • Neuroimaging in neuropsychiatric Lyme disease: Uses, abuses, and the future Brian Fallon, MD Columbia University College of Physicians & Surgeons • Pharmacologic properties of antibiotics and their relevence to LD Sam Donta, MD Boston University School of Medicine • Treatment Roundtable Joseph Burrascano, MD Southampton Hospital Sam Donta, MD Boston University School of Medicine Lesley Fein, MD Morristown Memorial Hospital Kenneth Liegner, MD Westchester Medical Center Dorothy Pietrucha, MD Cornell/NYHospital, Jersey Shore Medical Center •••• Target Audience This conference is designed for clinical professionals (including but not limited to Primary Care Physicians, Nurse Practitioners, Physician Assistants, Public Health Officers, Researchers and Veterinarians) and other health professionals (medical directors, risk managers) who wish to enhance their knowledge of Lyme disease and other tick-borne disorders. ••• Program Committee James Miller, PhD UCLA School of Medicine Sam Donta, MD Boston University School of Medicine Brian Fallon, MD Columbia University College of Physicians & Surgeons Ed Bosler, PhD Stonybrook School of Medicine Julie Rawlings, MPH Texas Department of Health Charles Pavia, PhD New York Medical College Ronald Schell, PhD University of Wisconsin School of Medicine ••• Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the College of Physicians & Surgeons of Columbia University and the Lyme Disease Foundation. The College of Physicians & Surgeons of Columbia University is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity. The College of Physicians & Surgeons designates this educational activity for a maximum of 15 hours in Category 1 credit towards the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. •••• Conference Goals a. Recognize the complex nature of Borrelia burgdorferi in both in terms of its antigenic variability and the host response to infection; b. Understand the rationale for different treatment approaches to Lyme Disease in animals and humans; c. Clarification of the role of the multiple diagnostic tests for Lyme disease; d. Understanding better the presentations of neurologic Lyme disease in children and adults, including the role of neuropsychological testing and neuroimaging; e. Understanding the epidemiology, clinical phenomenology, and diagnostic methods for detecting other vector-borne diseases, such as babesiosis, ehrlichiosis, Rocky Mountain spotted fever, and West Nile virus; f. Understanding the latest research regarding Lyme vaccines. Disclosure Before the program, all faculty will disclose the existence of any financial interest and/or other relationship(s) (e.g. employee, consultant, speaker’s bureau, grant recipient, research support, stock ownership or any other special relationship) they might have with a.) the manfacturer(s) of any commercial product(s) to be discussed during their presentation and/or b.) any commercial contributor to this activity. When unlabeled uses are discussed, these will also be indicated. ***************** REGISTRATION ******************* Mail to: Lyme Disease Foundation, 1 Financial Plaza, Hartford, CT 06103 860-525-2000 Fax 860-525-8425 Hotline 800-886-LYME Lymefnd@aol.com www.Lyme.org Fee includes: Attendance at scientific sessions, book of proceedings, lunch and breaks on both days, and receptions Friday (3/24) and Saturday (3/25) night. __ $275 February 16 to March 21 __ $325 March 22 to on-site __ $160 Poster Presenters - Posters still being accepted as of 3/7/00. Contact us for forms ; Graduate Students - w/University validation letter. __ $60 Reception Only __ $20 CME Certificate ***** Check Enclosed - Make checks payable to “Lyme Disease Foundation” **** Credit Card Charge __ Mastercard __ Visa __ American Express Card #_______________________________ Exp. ______ Signature________________________________________ Total Payment Enclosed: $ ____________ Full payment must accompany registration form. ** REGISTRANT #1 Name: Title/Position: Degree(s): Institution: Mailing Address: City: State Zip Phone: fax; email: ___ CME’s ___CME Certificate ($20 extra) Signature ** REGISTRANT #2 Name: Title/Position: Degree(s): Institution: Mailing Address: City: State Zip Phone: fax; email: ___ CME’s ___CME Certificate ($20 extra) Signature From owner-immuno@hgmp.mrc.ac.uk Wed Mar 8 05:14:15 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 4AF1117A58; Wed, 8 Mar 2000 05:14:15 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id FAA29203 for ; Wed, 8 Mar 2000 05:14:13 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id FAA04616 for immuno-list@hgmp.mrc.ac.uk; Wed, 8 Mar 2000 05:14:12 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: -- <76532.2302@CompuServe.COM> X-Newsgroups: bionet.immunology Subject: Re: CD40 protein Date: 8 Mar 2000 05:14:11 GMT Organization: Linscott's Directory Lines: 8 Message-ID: <8a4nj3$j2n$5@ssauraac-i-1.production.compuserve.com> References: X-Trace: ssauraac-i-1.production.compuserve.com 952492451 19543 149.174.242.227 (8 Mar 2000 05:14:11 GMT) X-Complaints-To: newsmaster@compuserve.com To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk CD40 Protein is available from Ancell Corp. in Minnesota. Check their website at: www.ancell.com -- Linscott's Directory of Immunological & Biological Reagents 815 Whitney Way, Petaluma, CA 94954 phone: 707-763-7098 fax: 707-763-8372 URL = www.linscottsdirectory.com From owner-immuno@hgmp.mrc.ac.uk Wed Mar 8 05:18:25 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id B381317A58; Wed, 8 Mar 2000 05:18:24 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id FAA29471 for ; Wed, 8 Mar 2000 05:18:22 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id FAA04622 for immuno-list@hgmp.mrc.ac.uk; Wed, 8 Mar 2000 05:18:22 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: -- <76532.2302@CompuServe.COM> X-Newsgroups: bionet.immunology Subject: Re: lectins Date: 8 Mar 2000 05:18:20 GMT Organization: Linscott's Directory Lines: 10 Message-ID: <8a4nqs$j2n$6@ssauraac-i-1.production.compuserve.com> References: <38B598EC.8DC9205C@bli.unizh.ch> X-Trace: ssauraac-i-1.production.compuserve.com 952492700 19543 149.174.242.227 (8 Mar 2000 05:18:20 GMT) X-Complaints-To: newsmaster@compuserve.com To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk Probably the best sources of lectins are the following companies: E-Y Laboratories ICN Biomedicals Sigma Chemical Co. -- Linscott's Directory of Immunological & Biological Reagents 815 Whitney Way, Petaluma, CA 94954 phone: 707-763-7098 fax: 707-763-8372 URL = www.linscottsdirectory.com From owner-immuno@hgmp.mrc.ac.uk Wed Mar 8 09:22:40 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 17C3017A58; Wed, 8 Mar 2000 09:22:38 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id JAA17971 for ; Wed, 8 Mar 2000 09:22:36 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id JAA07584 for immuno-list@hgmp.mrc.ac.uk; Wed, 8 Mar 2000 09:22:35 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f X-Originating-Host: 194.129.108.70 Organization: http://www.remarq.com: The World's Usenet/Discussions Start Here Subject: Re: glyconutritionals / how they may help with auto immune disease Lines: 8 From: dickie X-Newsgroups: bionet.immunology Message-ID: <0cbe8fc0.d17a6ff8@usw-ex0103-023.remarq.com> References: <1ca4f2e8.09b62113@usw-ex0110-075.remarq.com> <8a2nii$1k66$5@news1.wire.net.au> Bytes: 408 X-Wren-Trace: eBYzGxoDRA5FRAsdG1cFG0oNCQEABV8MHzoaBxoGBkIVCVkZFlcKC1QUHV0NXUVQTk5USFMQOCcmLkQhJg== Date: Wed, 08 Mar 2000 01:23:07 -0800 X-Complaints-To: wrenabuse@remarq.com X-Trace: WReNphoon4 952507351 10.0.2.23 (Wed, 08 Mar 2000 01:22:31 PST) To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk I actually think that nutrition is the key. Our modern diets do not completely sustain the body`s needs, hence the increase in immune system dysfunction.(Thats the theory anyway) That is why I take a glyconutritional supplement.See www.glycoscience.com * Sent from RemarQ http://www.remarq.com The Internet's Discussion Network * The fastest and easiest way to search and participate in Usenet - Free! From owner-immuno@hgmp.mrc.ac.uk Wed Mar 8 16:19:43 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id C36D717AA2; Wed, 8 Mar 2000 16:19:42 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id QAA29413 for ; Wed, 8 Mar 2000 16:19:41 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id QAA12747 for immuno-list@hgmp.mrc.ac.uk; Wed, 8 Mar 2000 16:19:40 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: Agnes Doumas X-Newsgroups: bionet.immunology Subject: I'm not a specialist... Date: Wed, 08 Mar 2000 17:18:30 +0100 Organization: diAx dplanet (postings do not reflect the views of diAx) Lines: 13 Message-ID: <38C67D56.894D125F@dplanet.ch> Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Trace: hs1b01h02-0.dplanet.ch 952532374 26274 212.35.56.184 (8 Mar 2000 16:19:34 GMT) X-Complaints-To: usenet@dplanet.ch X-Mailer: Mozilla 4.5 [fr]C-CCK-MCD {dplanet-1.0} (Win98; I) X-Accept-Language: fr-CH,en To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk Could anyone help me in answering to the following questions: Is it possible to raise antibodies against molecules such as Colchicine (some kind of molecules based on about 25-35 C, 35-40 H, 5-7 O, and possibly F, Na, N... and including about 3-4 cycles)? What may be the chances? What are the types of molecules (except proteins and carbohydrates)that are antigenic?? Thanks a lot for your answer! ADo From owner-immuno@hgmp.mrc.ac.uk Wed Mar 8 18:17:12 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 793C417A82; Wed, 8 Mar 2000 18:17:11 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id SAA13174 for ; Wed, 8 Mar 2000 18:17:08 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id SAA14284 for immuno-list@hgmp.mrc.ac.uk; Wed, 8 Mar 2000 18:17:06 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: fehr@biozentrum.uni-wuerzburg.de (Holger Fehr) X-Newsgroups: bionet.immunology Subject: Request for Kit-225 and/or NK-92 Date: 8 Mar 2000 18:17:05 -0000 Organization: BIOSCI/MRC Human Genome Mapping Project Resource Centre Lines: 21 Message-ID: <3.0.1.32.20000308191437.006a671c@mailserv.biozentrum.uni-wuerzburg.de> Mime-Version: 1.0 Content-Type: text/plain; charset="iso-8859-1" Content-Transfer-Encoding: 8bit X-Trace: niobium.hgmp.mrc.ac.uk 952539426 14282 193.62.192.80 (8 Mar 2000 18:17:06 GMT) X-Complaints-To: news@net.bio.net X-Received: from wbzx01.biozentrum.uni-wuerzburg.de (wbzx01.biozentrum.uni-wuerzburg.de [132.187.20.1]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id SAA13157 for ; Wed, 8 Mar 2000 18:17:02 GMT X-Received: from [132.187.20.190] (helo=wbz90) by wbzx01.biozentrum.uni-wuerzburg.de with smtp (Exim 3.13 #1) id 12Sl13-0000i6-00 for immuno@net.bio.net; Wed, 08 Mar 2000 19:17:01 +0100 X-Sender: fehr@mailserv.biozentrum.uni-wuerzburg.de X-Mailer: Windows Eudora Light Version 3.0.1 (32) X-To: immuno@hgmp.mrc.ac.uk X-MIME-Autoconverted: from quoted-printable to 8bit by hgmp.mrc.ac.uk id SAA13158 To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk Dear collegues, I´m looking for the human IL-2 dependent cell lines NK-92 and Kit225-K6. I would appreciate if someone form Germany or Europe could send me a few ml of these cells by mail. Thanks in advance, Holger Fehr ------------------------- Dr. Holger Fehr Inst. Physiological Chemistry II University of Wuerzburg Biocentre Am Hubland D-97074 Wuerzburg Germany --- From owner-immuno@hgmp.mrc.ac.uk Wed Mar 8 21:44:27 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id DD1FD17AA4; Wed, 8 Mar 2000 21:44:26 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id VAA05734 for ; Wed, 8 Mar 2000 21:44:24 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id VAA25382 for immuno-list@hgmp.mrc.ac.uk; Wed, 8 Mar 2000 21:44:23 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: "Graham Shepherd" X-Newsgroups: bionet.immunology Subject: Re: glyconutritionals / how they may help with auto immune disease Date: Wed, 8 Mar 2000 21:43:47 -0000 Organization: GXSN Lines: 14 Message-ID: <8a6hjj$4n3$1@gxsn.com> References: <1ca4f2e8.09b62113@usw-ex0110-075.remarq.com> <8a2nii$1k66$5@news1.wire.net.au> <0cbe8fc0.d17a6ff8@usw-ex0103-023.remarq.com> X-Trace: 952551859 1NNUCNF1GDB1FC393C gxsn.com X-Complaints-To: abuse@gxsn.com X-Priority: 3 X-MSMail-Priority: Normal X-Newsreader: Microsoft Outlook Express 5.00.2314.1300 X-MimeOLE: Produced By Microsoft MimeOLE V5.00.2314.1300 To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk dickie wrote in message news:0cbe8fc0.d17a6ff8@usw-ex0103-023.remarq.com... > I actually think that nutrition is the key. Our modern diets do > not completely sustain the body`s needs, hence the increase in > immune system dysfunction.(Thats the theory anyway) That is why > I take a glyconutritional supplement.See www.glycoscience.com > That's not a theory, it's a belief. If you're happy with it, fine. But believing the world is flat doesn't make it so. GS From owner-immuno@hgmp.mrc.ac.uk Wed Mar 8 22:28:49 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 3ABB317A68; Wed, 8 Mar 2000 22:28:47 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id WAA12978; Wed, 8 Mar 2000 22:28:45 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id WAA25851; Wed, 8 Mar 2000 22:28:44 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: "W. Fred Shaw" X-Newsgroups: bionet.molbio.hiv,bionet.immunology Subject: THE FAUCI FILES, 3( 38): Anti-Retroviral Therapy (ART) Corporate Revisionism, Point-Counterpoint Date: Wed, 08 Mar 2000 14:28:29 -0800 Organization: Frontier GlobalCenter Inc. Lines: 448 Message-ID: Reply-To: fredshaw@primenet.com Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Complaints-To: abuse@globalcenter.net X-Posted-By: @207.218.34.176 (fredshaw) X-Newsreader: Forte Agent 1.7/32.534 X-No-Archive: yes To: hiv-molbiol@hgmp.mrc.ac.uk, immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk THE FAUCI FILES, 3( 38): Anti-Retroviral Therapy (ART) Corporate Revisionism, Point-Counterpoint March 8, 2000 I am providing the following point-counterpoint analysis in response to Project Inform San Francisco's "Founding Director", Martin Delaney. As the leader of the pharmaceutical Corporate "Treatment Activists", Mr. Delaney receives pharmaceutical funding and his periodic product editorial defenses, publications and lobbying efforts are obviously on behalf of the pharmaceutical industry. Although Mr. Delaney and his organization claim to represent a patient "constituency", it is worth noting that Mr. Delaney's corporate commentary doesn't seriously consider the negative health implications of ART for his purported constituency: the HIV/AIDS patient (in fact, Mr. Delaney himself is HIV-negative). Finally, it is also worth noting that Mr. Delaney's Project Inform Board of Directors includes such luminaries as Aaron Diamond's Dr. David Ho and Dr. Robert Gallo, as well as others who have disclosed significant financial conflicts of interest with the pharmaceutical industry. W. Fred Shaw, Editor THE FAUCI FILES =============== Return-Path: Message-Id: <4.3.2.20000306230000.00dd4e10@127.0.0.1> Date: Mon, 06 Mar 2000 23:05:37 +0000 To: "aids" From: "Sr. Mary Elizabeth, OSM" Subject: [AEGiS] Response commentary to Clerici article posted March 5, 2000 >Submitted by Martin Delaney >Project Inform >-------------- > >There is nothing either new or unusual about this. Nothing could be further from the truth. > It is a phenomenon that has been reported and discussed repeatedly > among immunologists at meetings both privately and publicly. It does > not suggest a fault of therapy, but rather the success of it. Again, nothing could be further from the truth. FACT: this is the first time that a major scientist has separated those treated with antivirals from those who were antiviral naive for the purpose of measuring, comparing and contrasting the immunological parameters of the ART-treated versus the ART-naive (those who have never received ART treatment). Although the Clerici et al article in the journal AIDS (1/28/00) was NOT an evaluation of the clinical relevancy or usefulness of ART therapy (personal communication), no true scientist of Clerici's impartial and ethical stature should ever participate in product research evaluations and recommendations. Therefore, while remaining impartial as to the clinical usefulness or validity of ART, Dr. Clerici et al nonetheless reports objective findings that are rather startling and unambiguous: "Our results show that immune responses are potent in antiretroviral-naive but significantly reduced in HAART-treated patients with undetectable viraemia (< 500 copies/ml)." "T-cell proliferation to HIV-specific and HIV-unrelated antigens is potent in antiretroviral-naive but suppressed in HAART-treated individuals; . . ." "Results: Results showed immune profiles to be profoundly different in antiretroviral-naive in comparison with HAART-treated patients. Thus: (1) T-cell proliferation to HIV-specific and HIV-unrelated antigens is potent in antiretroviral-naive but suppressed in HAART-treated individuals; (2) interleukin-(IL)2, IL-12 and interferon gamma (IFNgamma) production is robust in naive patients; and (3) a high CCR5/low CXCR4 pattern of HIV coreceptors-specific mRNA is observed in naive but not in HAART-treated patients. > It does not suggest a fault of therapy, but rather the success of it. If one views immune suppression as a proper goal for a fatal pathogenic disease with a symptomatic hallmark of immune suppression, then ART is certainly a resounding, albeit deadly, "success". > This reduction in the HIV specific immune response is a direct result > of the reduction in viral replication as a result of therapy. Nothing could be further from the truth. Immune suppression by these ART drug therapies occurs independently of the individual's viral load. Thus, the suppression of the entire immune response -- not merely the HIV-specific response -- is a primary and direct effect of these drugs rather than a downstream effect of viral reduction. The reduction of ALL immune responses, including such things as the candida and flu antigens (Clerici et al, AIDS, 1/28/00), were only observed in those using the ART drugs: 1. Treatment "failures" who use these ART drugs, achieve non-detectable viral loads but later experience viral rebound do NOT experience a concomitant "rebound" in their HIV-specific immune response, as Mr. Delaney suggests. 2. Treatment "failures" who use these ART drugs and do NOT achieve significant viral load reduction, will nonetheless suffer the same ART-induced immune suppression as those who do achieve non-detectable viral loads. 3. Treatment "naives" who never use these drugs and have low and undetectable viral loads do NOT experience the loss of immune responses -- HIV-specific or otherwise -- that are reported only for the ART-treated. Mr. Delaney merely parrots the superstition promulgated by the pharmaceutical industry that claims that these drugs are specific to the HIV virus. Nothing could be further from the truth. > What maintains that response in naive (untreated) patients > is the constant stimulation of the immune system by viral replication. This focus on the HIV-specificity subset of the immune response merely detracts from the immune response as a whole, which is clearly being destroyed by the ART drugs. FACT: The Clerici article clearly makes the unambiguous distinction between the HIV-specific and other immune responses: "T-cell proliferation to HIV-specific and HIV-unrelated antigens is potent in antiretroviral-naive but suppressed in HAART-treated individuals; . . ." The reduction of HIV viral load does NOT account for the loss of immune responses to other antigens, which were "defective" ONLY in the ART-treated, such as the candida- and flu-specific antigens. > Once that is suppressed a few logs, the immune system no longer > sees much HIV and therefore stops attempting to respond. Rubbish. The immune systems of the ART-naive don't "stop attempting to respond" when their viral load is "suppressed a few logs" in the absence of these drugs. Further, as stated above, those who use ART and do NOT achieve reductions in viral load will nonetheless experience the same decline in immune responsiveness as those who do achieve non-detectable reductions in the HIV viral load. >In people treated since the earliest stages of infection, it appears >that this HIV specific immune response is sometimes preserved, or at >least the capacity for making it. At best, this statement is a very poor advertisement for using these immune-destroying drugs for a disease of declining immunity. Clearly, ART suppresses ALL immune responses directly, NOT as a secondary effect of reducing the HIV viral load. Terms such as "sometimes preserved" and "capacity for making" are, in this case, simple artifacts of Delaney's distance from the science. > In some of the STI (therapy interruption) research, this response > has been triggered after people go off therapy for a while. Dr. Clerici et al detailed the overbroad suppression of the immune response in the ART treated while the immune responses of the ART-naive remain intact. Mr. Delaney offers no explanation for the intact immune responses of the treatment naive with low and undetectable viral load. Are the immune responses (HIV-specific and otherwise) of the treatment-naive suppressed in the presence of viral control? Of course not. Do the ART-naive retain their immunological response to the flu and candida antigen? Yes. Are the immune responses (HIV-specific and otherwise) of the ART treated suppressed in the presence of viral control? Yes. Do the ART-treated retain their immunological response to the flu and candida antigens? No. (see references below) > Although the numbers are still relatively small, there is some > small, there is some indication that repeated cycles of on/off therapy > can strengthen the natural immune response. The claim that a "small number" or a "small indication" of ART users who engage in "on/off therapy" will "strengthen the natural immune response" is made in the absence of comparative data involving the treatment naive. Such unscientific studies in the absence of placebos or comparative data involving those who are NEVER ART-treated have clearly dominated the approval and recommendation process for these ART drug therapies for the past 13 years -- almost to the exclusion of anything else. In fact, in this "small number" of those who use ART without measurable loss of immune responses, Occam's Razor could favor only one conclusion: these individuals would have done the same or better had they not used the ART drugs in the first place. > More than a dozen people are currently being studied who underwent > anywhere from one to three cycles of treatment interruption and > who now maintain undetectable viral load without further help from > antiviral drugs. Absent a comparative group of treatment-naive, Delaney's "dozen people" anecdote may be interesting, but offers little or nothing in terms of scientific evidence, especially when we aren't being advised of the pre-treatment viral load of these purported individuals. To rely on such pie-in-the-sky studies after 13 years of these toxic and dangerous pharmaceuticals as the "standard of care" is as irresponsible as it is intentional in the deaths of those who die as a direct result of using these drugs. >It has also been noted that each time a treatment interruption cycle is >used, it typically takes longer for viral load to become detectable >again. Obviously this observation could better be explained as an artifact of the cycles of ART-induced immune suppression, together with the dynamics of multi-drug resistance (MDR). >Until recently, this phenomenon had only been seen in people treated >since primary infection. A new report was released at the VII >International Retrovirus Conference which showed a similar outcome in a >small number of chronically infected patients as well. For the most part, the conference reports upon which Delaney relies are little more than publicity stunts and appeals for drug company research funding (they were never intended for peer-reviewed journal publication). The reliance on non-peer-reviewed and journal-unpublished anecdotal data from pharmaceutical conferences is not only typical of poor salesmanship, but clearly demonstrates the scientific and clinical bankruptcy of ART itself. >Taken together, it might be suggested that the way to avoid loss of the >HIV-specific response requires two steps. Once again, the "HIV-specific" sales tactic avoids the most important issue: the overbroad loss of ALL immune responses, not merely those related to HIV-specificity. > First, it seems clear that the best chances for maintaining the > capacity to mount that response is to treat people early Mr. Delaney has struggled to make these issues anything but clear. To use ART immune-suppressing drugs to suppress the immunological control which, in the absence of these drugs, delays the onset of symptomatic disease for a decade or longer, could only portend a grim outlook for the patient. Further, Mr. Delaney's lack of scientific candor is as abysmal as his lack of scientific evidence to sustain the continued use of the ART 13-year standard-of-care, which, as we can all plainly see, has never been "standardized" nor has it offered "care" in terms of preserving the competence of the innate immune response. If a therapy for a disease of immune suppression fails to protect and preserve the immune health of the patient, but rather does harm to these life-critical protective processes, then what good is it? > (this, however, must be balanced against the earlier > risks of side effects). The early onset of "side effects" from ART "early use" is as obvious as it is destructive of every tissue and organ system of the body. Unfortunately, these "hit hard and hit early" patients will most likely die of organ, vascular and/or a variety of immune failures prior to the time they would be expected to develop AIDS. This can be seen in the preponderance of obituary reports which reveal "sudden death" which is often characterized as "not AIDS related". The very recent death of the Israeli Diva who died of "organ failure" offers a case in point and begs an answer to the question that arose after the approval of these ART drugs: what causes "organ failure" in those with HIV infection, if not the ART drugs? > Secondly, preliminary data suggest that treatment needs to be > interrupted periodically to permit the virus to be > "reintroduced" to the immune system periodically. It was only a few short years ago that Mr. Delaney authored an editorial in the Project Inform "PI Perspective", in which he emphasized the life-critical importance of NEVER missing a single dose of the ART regimen. Mr. Delaney's precise words began with the alarmist admonition: "You have one chance to get it right ..." Today, Martin Delaney is promoting the ART product line with quite a different spin that underscores the "benefit" of ART that is "interrupted periodically". What corporate product spin will Delaney offer us a year or two from now? Further, as one of the favored corporate spins, the "potential -but-not-quite-a-cure" sales tactic is not without precedent (e.g. the implications for Delaney's latest spin on the ART treatment theory: "permit the virus to be 'reintroduced' ... "), as this was the original impetus for these drugs gaining initial FDA approval in the first place. Aaron Diamond's Dr. David Ho (on Mr. Delaney's Project Inform Board of Directors) played no small role in purveying this false treatment claim in his 1996 claim for the ART "1 year cure", which he later clarified as his "mathematical cure". Dr. Ho's superstitious claims have yet to materialize, however here they rematerialize in Delaney's own words that unambiguously imply that HIV virus "leaves the body" as a result of using the ART drugs. Mr. Delaney, however, takes the superstition to the next marketing level with the implication that when the drugs are stopped, the virus will mysteriously be "reintroduced", as if that is something that is good, healthy and desirable. Such is the nature of medical hucksterism. To conclude this point-counterpoint analysis, it is essential to re-examine the scientific rationale for Dr. Fauci's ART "standard of care", which originally focused on these drugs as potent weapons that would facilitate the reconstitution of the immune response through the decrease of the viral load, which, in turn, would result in increases of the CD4+ T-cell count. (Interestingly, under NIAID Director Dr. Anthony Fauci's tutelage, Mr. Delaney is listed by NIH/NIAID as a contributor to the development of the ART "Standard of Care" recommendations, despite his lack of medical or scientific credentials). While Clerici et al, Pantaleo et al and others have recently revealed that "HAART (ART) does not necessarily augment the immune response", then this can no longer be a rationale for using HAART when the immune responses required to control opportunistic infections and neoplasms are not only NOT being augmented, but to the contrary -- these immune responses (e.g. including the flu and candida antigens, Clerici et al, AIDS, 1/28/00) are being directly suppressed and harmed by ART! Finally, the proposition that immunomodulators are needed to "augment" ART is implicitly flawed when one considers that these immunomodulators are merely needed to compensate for the immune harm that is done by the first treatment (ART). The treatment question remaining is obvious: can immunomodulators even begin to compensate for the immune destruction done by ART, and if so, wouldn't they be even more valuable in the control of the HIV virus when they are used alone and in the absence of ART, rather than as a medical intervention that chases the harm done by ART, a therapy that can no longer claim a valid "immune augmenting" rationale? Isn't it rather revealing that these are the questions that Mr. Delaney, Dr. Fauci, Dr. Ho and their various corporate minions and sponsors are NOT bothering to ask for the betterment of what Delaney purports to be his "patient constituency"? W. Fred Shaw, Editor THE FAUCI FILES ======== The following articles by elite scientists, including Nobelist Rolf Zinkernagel, provide conclusive evidence that HAART: (1) increases blood CD4 T-cells -- not by creating NEW CD4 T-cells, but rather by inducing the redistribution of the CD4 cells that are ALREADY present in the lymphoid tissues (thus, the lab CD4 measure becomes a superstitious treatment artifact of no true value). (2) increases CD4 T-cells which are suppressors, (3) suppresses immune responses, (4) suppresses cytokine production, and (5) virological failure does not involve drug-resistant HIV-1 mutations: (1) Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, Sillers M, Mitsuyasu RT, Kilby JM. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999 May 15;103(10):1391-1398. (2) HAART-induced increases in blood lymphocytes are of the CD4+ CD25+ phenotype (along with CD38 and CD44) (David Ho, 9th International Congress of Immunology, 1995), which are antigenic nonspecific suppressors (Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000 Jan 1;164(1):183-90). (3) Clerici M,* Seminari E, Suter F, Castelli F, Pan A, Biasin M, Colombo F, Trabattoni D, Maggiolo F, Carosi G, Maserti R (for the Master Group). Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia. AIDS 2000 Jan 28; 14:109-116. (3) Soudeyns H, Campi G, Rizzardi GP, Lenge C, Demarest JF, Tambussi G, Lazzarin A, Kaufmann D, Casorati G, Corey L, Pantaleo G. Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. Blood 2000 Mar 1;95(5):1743-1751. (3) Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998 Oct 1;12:1833-1844 (3) Andre P, Groettrup M, Klenerman P, de Giuli R, Booth BL Jr, Cerundolo V, Bonneville M, Jotereau F, Zinkernagel RM, Lotteau V. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A 1998 Oct 27;95(22):13120-13124 (4) Al-Harthi L, Roebuck KA, Kessler H, Landay A. Inhibition of cytokine-driven human immunodeficiency virus type 1 replication by protease inhibitor. Journal of Infectious Diseases 176:1175-1179 (Nov 1997). (4) Andersson J, Fehniger TE, Patterson BK, Pottage J, Agnoli M, Jones P, Behbahani H, Landay L. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998 Jul 30;12:F123-F129. (5) Markowitz M. Resistance, fitness, adherence, and potency: mapping the paths to virologic failure. JAMA 2000 Jan 12;283(2):250-1 (5) Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir- containing regimens. JAMA 2000 Jan 12;283(2):229-34 ======= From owner-immuno@hgmp.mrc.ac.uk Thu Mar 9 00:22:04 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 2BD6117A75; Thu, 9 Mar 2000 00:22:02 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id AAA27339 for ; Thu, 9 Mar 2000 00:21:57 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id AAA27129 for immuno-list@hgmp.mrc.ac.uk; Thu, 9 Mar 2000 00:21:55 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: Simon Worrall X-Newsgroups: bionet.immunology Subject: Re: I'm not a specialist... Date: Thu, 09 Mar 2000 10:20:12 +1000 Organization: University of Queensland Lines: 14 Message-ID: <38C6EE3C.64BEA4B7@biosci.uq.edu.au> References: <38C67D56.894D125F@dplanet.ch> Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Trace: bunyip.cc.uq.edu.au 952561313 14381 130.102.116.49 (9 Mar 2000 00:21:53 GMT) X-Complaints-To: news@uq.edu.au X-Mailer: Mozilla 4.7 [en] (Win98; I) X-Accept-Language: en To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk You need a mol wt of ~1.5 kDa before something is immunogenic. To raise antibodies against smaller molecules they must be attached to a carrier molecule, usually a protein. They are then HAPTENS and immunogenic. Antibodies can then be raised to the hapten and the carrier. Glycolipids and nucleic acids are also immunogenic together with large xenobiotic compounds. Simon Worrall Lecturer in Biochemistry University of Queensland Australia From owner-immuno@hgmp.mrc.ac.uk Thu Mar 9 09:20:17 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 720CA17A58; Thu, 9 Mar 2000 09:20:15 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id JAA05451 for ; Thu, 9 Mar 2000 09:20:11 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id JAA03478 for immuno-list@hgmp.mrc.ac.uk; Thu, 9 Mar 2000 09:20:09 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: rubendaniel@my-deja.com X-Newsgroups: bionet.immunology Subject: fetal calf serum Date: Thu, 09 Mar 2000 09:13:00 GMT Organization: Deja.com - Before you buy. Lines: 10 Message-ID: <8a7pur$56a$1@nnrp1.deja.com> X-Article-Creation-Date: Thu Mar 09 09:13:00 2000 GMT X-Http-User-Agent: Mozilla/4.0 (compatible; MSIE 5.0; Windows NT; DigExt) X-Http-Proxy: 1.1 x21.deja.com:80 (Squid/1.1.22) for client 193.61.205.152 X-MyDeja-Info: XMYDJUIDrubendaniel To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk Hi everybody, This is really a curiosity more than technical problem. What's the reason for using fetal calf serum to make cell cultures??. Why not, for example, newborn calf is usually cheaper?. All the companies I called said that such serum came from animals less than 10-12 days old, so if the animal is healthy what's the reason for not using that thing? Sent via Deja.com http://www.deja.com/ Before you buy. From owner-immuno@hgmp.mrc.ac.uk Thu Mar 9 14:36:44 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 70FD017AAD; Thu, 9 Mar 2000 14:36:43 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id OAA07575 for ; Thu, 9 Mar 2000 14:36:41 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id OAA08089 for immuno-list@hgmp.mrc.ac.uk; Thu, 9 Mar 2000 14:36:40 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: Pierre =?iso-8859-1?Q?Commer=E7on?= X-Newsgroups: bionet.immunology Subject: Ventana ???? Date: Thu, 09 Mar 2000 15:36:15 +0100 Organization: C.I.S.M. Universite Claude Bernard Lyon 1 / INSA de Lyon Lines: 17 Message-ID: <38C7B6DF.AAC5D450@univ-lyon1.fr> Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Mailer: Mozilla 4.6 [fr] (Win95; I) X-Accept-Language: fr To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc.ac.uk Precedence: bulk Hello, I'am very interested to buy an Ventana immunology automatized system. Some people say that the results with it are not good (important background...) What is your experience with Ventana immunology automatized system ? Have you some problems ? Thanks a lot Pierre pcomm@univ-lyon1.fr From owner-immuno@hgmp.mrc.ac.uk Thu Mar 9 18:07:31 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id B076417AAC; Thu, 9 Mar 2000 18:07:30 +0000 (GMT) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id SAA02573 for ; Thu, 9 Mar 2000 18:07:28 GMT Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id SAA10828 for immuno-list@hgmp.mrc.ac.uk; Thu, 9 Mar 2000 18:07:27 GMT X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: sgraffi@gmx.net (Sebastian Graffi) X-Newsgroups: bionet.immunology Subject: BAL cytokines Date: 9 Mar 2000 18:07:26 -0000 Organization: BIOSCI/MRC Human Genome Mapping Project Resource Centre Lines: 13 Message-ID: <3.0.6.32.20000309191048.007f2de0@unet.univie.ac.at> Mime-Version: 1.0 Content-Type: text/plain; charset="us-ascii" X-Trace: niobium.hgmp.mrc.ac.uk 952625247 10826 193.62.192.80 (9 Mar 2000 18:07:27 GMT) X-Complaints-To: news@net.bio.net X-Received: from unet.univie.ac.at (unet.univie.ac.at [131.130.230.7]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id SAA02550 for ; Thu, 9 Mar 2000 18:07:24 GMT X-Received: from Apollo (apollo.imm.univie.ac.at [131.130.98.69]) by unet.univie.ac.at (8.9.3/8.9.3) with SMTP id TAA83522 for ; Thu, 9 Mar 2000 19:07:23 +0100 X-Sender: a8601597@unet.univie.ac.at X-Mailer: QUALCOMM Windows Eudora Light Version 3.0.6 (32) X-To: immuno@hgmp.mrc.ac.uk To: immuno@hgmp.mrc.ac.uk Sender: owner-immuno@hgmp.mrc